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Abstract 
Background: Most in vitro studies investigating nanomaterial pulmonary toxicity poorly correlate to in vivo inhala‑
tion studies. Alveolar macrophages (AMs) play an outstanding role during inhalation exposure since they effectively 
clear the alveoli from particles. This study addresses the applicability of an in vitro alveolar macrophage assay to distin‑
guish biologically active from passive nanomaterials.
Methods: Rat NR8383 alveolar macrophages were exposed to 18 inorganic nanomaterials, covering AlOOH, BaSO4, 
CeO2, Fe2O3, TiO2, ZrO2, and ZnO NMs, amorphous SiO2 and graphite nanoplatelets, and two nanosized organic 
pigments. ZrO2 and amorphous SiO2 were tested without and with surface functionalization. Non‑nanosized quartz 
DQ12 and corundum were used as positive and negative controls, respectively. The test materials were incubated 
with the cells in protein‑free culture medium. Lactate dehydrogenase, glucuronidase, and tumour necrosis fac‑
tor alpha were assessed after 16 h. In parallel, H2O2 was assessed after 1.5 h. Using the no‑observed‑adverse‑effect 
concentrations (NOAECs) from available rat short‑term inhalation studies (STIS), the test materials were categorized as 
active (NOAEC < 10 mg/m3) or passive.
Results: In vitro data reflected the STIS categorization if a particle surface area‑based threshold of <6000 mm2/mL 
was used to determine the biological relevance of the lowest observed significant in vitro effects. Significant effects 
that were recorded above this threshold were assessed as resulting from test material‑unspecific cellular ‘overload’. 
Test materials were assessed as active if ≥2 of the 4 in vitro parameters undercut this threshold. They were assessed as 
passive if 0 or 1 parameter was altered. An overall assay accuracy of 95 % was achieved.
Conclusions: The in vitro NR8383 alveolar macrophage assay allows distinguishing active from passive nanomateri‑
als. Thereby, it allows determining whether in vivo short‑term inhalation testing is necessary for hazard assessment. 
Results may also be used to group nanomaterials by biological activity. Further work should aim at validating the 
assay.
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Background
With the advent of nanotechnology, the importance of 
adequately assessing the human health impacts of nano-
materials (NMs) is widely recognized. Generally, NMs 
are covered by chemicals legislation, such as the EU 
regulation no. 1907/2006 on the registration, evaluation, 
authorisation and restriction of chemicals (REACH [1]). 
Taking into account the abundance of NM modifications 
in regard to particle size, shape, or surface properties and 
the very broad definition for ‘nanomaterial’ as it has been 
laid down, e.g., in EU Commission [2], it is expected that 
the safety of a substantial number of NMs will have to be 
assessed to meet the REACH information requirements 
[3]. At the same time, however, the REACH regulation 
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requires that animal testing should only be undertaken as 
a last resort. Concordantly, Directive 2010/63/EU on the 
protection of animals used for scientific purposes [4] pre-
scribes implementation of the 3Rs principle to replace, 
reduce and refine animal testing [5].
To promote the collection of relevant data for the safety 
assessment of a representative set of NMs, the Organi-
sation for Economic Co-operation and Development 
Working Party on Manufactured Nanomaterials (OECD 
WPMN) has launched a Sponsorship Programme for 
the testing of manufactured nanomaterials [6, 7]. This 
programme further aims at establishing the role of 3Rs 
methods for NM testing [6]. With inhalation generally 
being one of the main routes of NM exposure both for 
workers and consumers [8, 9], the WPMN has proposed 
a short-term rat inhalation study (STIS [10]) as a suitable 
test method to reduce and refine repeated-dose sub-acute 
inhalation toxicity testing. The STIS provides informa-
tion on early elements of NM-induced pathogenesis as 
well as on the reversibility, persistence or progression of 
effects. Furthermore, NM lung burden and potential for 
extra-pulmonary translocation may be investigated in the 
STIS [9–11].
Although the STIS allows reducing animal numbers, 
suffering, and distress as compared to the 28-day sub-
acute inhalation toxicity study described in OECD Test 
Guideline (TG) 412 [12], it still uses sentient animals. 
There is also no in vitro test method available that may be 
used in a tiered approach to decide whether or not in vivo 
testing, beginning with the STIS, should be required for 
regulatory hazard assessment. Up to now, numerous dif-
ferent in  vitro test systems encompassing submersed or 
air–liquid exposed cells of mostly pulmonary origin have 
been investigated in combination with a variety of differ-
ent endpoint detection methods [13–20]. However, the 
available in vitro results are inconsistent, and to the best 
of the authors’ knowledge, there is no in vitro assay that 
allows reliably predicting the in  vivo effects of inhaled 
NMs [21].
Against this background, it was the goal of the cur-
rent study to develop an in  vitro assay that is suitable 
for routine regulatory testing of NM inhalation toxic-
ity. In choosing an appropriate test system, it was taken 
into account which pulmonary cells are predominantly 
exposed to inhaled NMs. Depending on their aerody-
namic diameter, inhaled particles may reach the deep 
regions of the pulmonary parenchyma [22]. Upon inter-
action with lung surfactant proteins and lipids, dis-
persed or agglomerated particles may deposit on the 
inner alveolar surface. In contrast to the bronchial walls 
that are protected by a mucus layer which is expelled 
by the underlying ciliated epithelium, alveolar cells 
are much more vulnerable. Nevertheless, within the 
alveoli particles may be engulfed by alveolar macrophages 
(AMs), which may then be removed via the mucociliary 
escalator [23–26]. Although nanoparticles were originally 
believed to be too small to be rapidly cleared by AMs, the 
dominant role of these cells for the uptake and clearance 
also of nanoparticles has been shown in various studies 
[27–29] and is now widely accepted. Only a very small 
fraction of inhaled NMs appears to permeate the intact 
lung epithelial barrier thereby potentially becoming sys-
temically available [30–33]. It has also been suggested 
that nanoparticles may transiently enter the alveolar 
epithelium or the interstitium, thereby delaying seques-
tration by AMs [34–36]. Although the full details of the 
early steps of NM deposition, lung surfactant interac-
tion, and particle transport are still under investigation, it 
goes undisputed that AMs harbour the major fraction of 
inhaled NMs, at least after acute or sub-acute exposure 
[35, 37], and that these cells play a central role in clearing 
the lung from inhaled NMs.
A multitude of endpoints may be studied to evalu-
ate the biological responses of AMs that are exposed to 
NMs. AMs are specialized to fend off microbial inva-
sions by non-specific, nicotinamide adenine dinucleotide 
phosphate-oxidase (NAPDH) oxidase-regulated oxida-
tive burst. Unsurprisingly, also inhaled particles may 
elicit this type of response, at least upon increased parti-
cle load [38, 39]. Formation of extracellular reactive oxy-
gen species (ROS) may elicit indirect oxidative damage of 
adjacent cells [40]. Moreover, AMs, forming part of the 
non-specific immune system, may initiate and orches-
trate immunological processes by releasing chemokines 
and cytokines [41]. Together with the formation of extra-
cellular ROS/H2O2 and/or nitrogen monoxide, AMs are 
known to release different pro-inflammatory mediators 
(e.g., tumour necrosis factor α (TNF-α); interleukins (IL-
1, IL-6, IL-8); or monocyte chemoattractant protein-1 
(MCP-1)) and fibrogenic mediators [e.g., transforming 
growth factor β (TGF-b); osteopontin; or platelet-derived 
growth factor (PDGF)] [10, 11, 41–45]. Some of these 
mediators may serve as chemoattractants for blood gran-
ulocytes, or they may enhance pulmonary inflammatory 
processes [46]. Likewise, AMs may release lytic and other 
enzymes upon (nano)particle stimulation which in return 
may activate or stimulate exocytosis [47–49].
Bioactive particles or high particle load may also impair 
macrophage functions, such as their motility or bacteri-
cidal capacity, which may eventually lead to the disrup-
tion of cell membrane integrity [23, 24, 50–52]. Although 
AMs are readily recruited from blood monocytes, any 
weakening of the intra-pulmonary AM population will 
affect lung clearance thereby enhancing the risk for the 
evolvement of lung diseases [53].
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Since the pulmonary effects of NMs upon short-term 
inhalation exposure are predominantly AM-mediated, it 
appears promising to study essential biological responses 
of AMs in vitro when aiming at predicting in vivo short-
term inhalation effects. This principle was established 
long before the term nanotoxicology was coined. Rehn 
et  al. [54, 55] incubated a defined number of primary 
AMs lavaged from the lungs of guinea pigs and rats with 
a defined mass of micron-scaled particulate matter, such 
that a mean particle burden/AM could be calculated. 
Rehn et  al. [55] designed their in  vitro studies to cover 
the plausible in  vivo particle burden/AM inside the rat 
lung. Assuming that the upper in vitro threshold corre-
sponds to the upper in vivo rat lung threshold since pri-
mary rat AMs widely resemble in vivo rat AMs and these 
cells sequester the vast majority of inhaled particles, the 
relevant concentration range was estimated from the 
maximum rat lung burden divided by the number of 
AMs/lung. This number is fairly constant (i.e., 1–2 × 107) 
in healthy, unrestrained rats [55, 56]. Accordingly, Bruch 
et al. [57] calculated a mean particle burden of ≤120 pg/
AM as a realistic in vivo upper value. Interestingly, direct 
measurements carried out on AMs extracted from the 
bronchoalveolar lavage fluid (BALF) of rats exposed to 
30  mg/m3 poorly soluble AlOOH NMs by inhalation 
for 28 days revealed a cell burden of approx. 90 pg/AM 
[58]. Altogether, these findings underline that cultured 
AMs may be exposed to doses that resemble in vivo con-
ditions. This is a promising starting point for in vitro-in 
vivo comparisons.
An in  vitro assay suitable for regulatory toxicity test-
ing should include biologically relevant, but easy to 
measure endpoints. This will increase the predictive 
value of the in vitro data. The model originally proposed 
by Rehn et  al. [55] comprised TNF-α (as a major pro-
inflammatory cytokine), ROS/H2O2 (as a major inducer 
of oxidative stress), β-glucuronidase (GLU; indicating 
macrophage activation [44] and/or membrane damage), 
and AM bactericidal capacity (revealing changes in the 
viability of the particle-laden AMs). Since these four end-
points (or parameters) were visualized as four vectors, 
the in vitro assay was termed ‘vector model’. The ‘vector 
model’ has been used to assess the in vitro effects of dif-
ferent materials relevant for the occupational setting [50, 
57, 59].
In the present study, the concept of the ‘vector model’ 
was transferred to NR8383 cells, an AM cell line derived 
from rat lung lavage cells [60, 61]. Over many passages, 
NR8383 cells maintain their typical AM-like size, appear-
ance, and phagocytic as well as immunological proper-
ties. They have been observed to react to test material 
exposure by the formation and release of different pro-
inflammatory and fibrogenic cytokines and chemokines, 
including TNF-α, IL-1, TGF-β and PDFG [60–65]. 
NR8383 cells have further been used to measure oxida-
tive burst and ROS production as well as mitochondrial 
damage [61, 66]. On the gene expression level, differ-
ent markers for oxidative damage, inducible nitric oxide 
synthase expression [64], inflammation, autophagy, and 
apoptotic balance were recorded in NR8383 cells [67].
Just as macrophages in general [68], NR8383 cells are 
more sensitive to test materials than e.g., lung epithelial 
cells [69]. NR8383 have been used for the in vitro testing 
of a variety of NMs including functionalized amorphous 
SiO2, indium tin oxide, alumina, Al2O3, ultrafine TiO2, 
(multi-walled) carbon nanotubes ((MW)CNTs), various 
copolymers and also heparin nanoparticles [64, 66, 69–
75]. Generally, these studies differed with respect to fun-
damental aspects of the test protocol, such as medium 
composition, size of culture vessels, cell density, or incu-
bation period. Furthermore, oftentimes well established 
materials serving as negative or positive controls (NCs, 
PCs) were not included. This, however, is a mandatory 
prerequisite for regulatory testing. It further forms an 
essential part of benchmark in vitro testing. Benchmark 
testing implies the comparative assessment of new mate-
rials against ‘benchmark materials’ which were previously 
tested and evaluated according to standard criteria. This 
benchmark testing is expected to constitute an important 
pillar in the safety assessment of the abundance of NM 
modifications available [21, 76].
In the present study, a test protocol was set up and 
applied that largely followed up on the testing strat-
egy of the ‘vector model’ published by Bruch et  al. [57, 
77, 78], concordantly using non-nanosized corundum 
(Al2O3) and quartz DQ12 as NC and PC, respectively. 
Corundum was further used as negative (albeit micron-
scaled) benchmark material, against which the in  vitro 
test data were compared. The permanent NR8383 cells 
were selected as test system, and test materials were 
applied under protein-free cell culture conditions since 
protein supplementation of the culture medium has 
been observed to mitigate the in vitro cellular effects of 
NMs [21]. The selected endpoints comprised NM effects 
on membrane disruption and macrophage activation 
that were assessed by measuring cellular release of lac-
tate dehydrogenase (LDH) and GLU. Pro-inflammatory 
reactions were assessed by measuring cellular release of 
bioactive TNF-α, and induction of oxidative stress was 
assessed by measuring the formation and release of H2O2.
Using this testing strategy, 18 inorganic NMs were 
assessed, covering metal oxides and sulphates (AlOOH, 
BaSO4, CeO2, Fe2O3, TiO2, ZnO, and ZrO2), precipitated, 
pyrogenic and colloidal amorphous SiO2 and graph-
ite nanoplatelets, and two nanosized organic pigments. 
CeO2, ZrO2 and colloidal amorphous SiO2 were tested 
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without and with doping or surface functionalization. 
Thereby, the selected test materials covered a broad range 
of chemically different, but economically important 
nanosized materials.
The in vitro data collected performing the NR8383 AM 
assay evaluating LDH, GLU, TNF-α and H2O2 release 
were used to obtain an overview on the cellular effects 
of the altogether 20 test materials. Moreover, the pre-
sent study was conceived to assess the applicability of the 
in  vitro NR8383 AM assay within a tiered approach for 
regulatory NM hazard assessment. An example for such a 
tiered approach is the DF4nanoGrouping Decision-mak-
ing framework for the grouping and testing of NMs put 
forward by Arts et al. [33, 79]. Within a tiered approach, 
the information gathered during the early non-animal 
tiers is used to determine whether higher tier in vivo test-
ing is relevant for hazard assessment, or not.
Accordingly, it was assessed whether the data from the 
in  vitro NR8383 assay allow recognizing passive NMs 
that will not elicit specific toxic effects upon inhalation 
exposure. If a NM can be assigned to the group of pas-
sive NMs based on the outcome of the in vitro NR8383 
AM assay along with material and functional proper-
ties, in  vivo inhalation studies may not be required for 
its hazard assessment. Further, it was assessed if the 
in vitro NR8383 AM assay allows identifying active NMs 
which elicit specific toxic effects upon inhalation expo-
sure. Active NMs require further data and sub-grouping 
using in vivo inhalation testing to facilitate their hazard 
assessment.
Against this background, the in  vitro data were used 
to develop a prediction model for the in  vitro NR8383 
AM assay that appeared best suited to distinguish pas-
sive from active NMs. As a ‘gold standard’ for the cate-
gorization of active and passive NMs, the findings from 
STISs (or sub-acute inhalation studies) available for all 20 
test materials [10, 11, 58, 79–82] were used. A rat STIS 
no-observed-adverse-effect concentration (NOAEC) 
of <10 mg/m3 was set as threshold value indicating NM 
activity, whereas NMs with STIS NOAECs of 10 mg/m3 
or higher were assessed as passive [33, 79]. Applicability 
of the in vitro NR8383 AM assay within a tiered approach 
for regulatory hazard assessment was evaluated by com-
paring the in  vitro assignments of the test materials as 
either active or passive to the in vivo categorization.
Methods
Test materials
Ten of the altogether 18 inorganic NMs of the present 
study were used in the German Federal Ministry for 
Education and Research-funded projects NanoCare (i.e., 
AlOOH, BaSO4 NM-220, nano-CeO2, Al-doped CeO2) 
and NanoGEM (i.e., ZrO2.TODA, ZrO2.acrylate, colloidal 
SiO2.naked (Levasil® 200) and its surface-functionalized 
variants SiO2.PEG, SiO2.amino, SiO2.phosphate). Details 
on their physico-chemical characterization have been 
published by Driessen et  al. [83], Kroll et  al. [17], Kuh-
lbusch et al. [84], Hellack et al. [85], Izak-Nau and Voetz 
[86], and Landsiedel et al. [11].
Of these test materials, AlOOH (boehmite) was origi-
nally supplied by Sasol (Germany); BaSO4 NM-220 by 
Solvay (Belgium); Al-doped CeO2 by Evonik Industries 
AG (Germany); ZrO2.TODA and ZrO2.acrylate by itN 
Nanovation AG (Germany); SiO2.naked by AkzoNobel 
AB (Sweden); and nano-CeO2, SiO2.PEG, SiO2.amino, 
and SiO2.phosphate by BASF SE (Germany).
Just as BaSO4 NM-220, also six further NMs (i.e., TiO2 
NM-105, ZnO NM-111, precipitated SiO2 NM-200 
and pyrogenic SiO2 NM-203, CeO2 NM-211 and CeO2 
NM-212) were representative NMs of the OECD WPMN 
Sponsorship Programme for the Testing of Manufac-
tured Nanomaterials. These six NMs were obtained from 
the EU Commission’s Joint Research Centre (JRC, Ispra, 
Italy). Detailed characterization data for these OECD 
representative NMs have been published by Singh et al. 
[87, 88] and Rasmussen et  al. [89, 90]. Of note, NM-x 
numberings (e.g., ZnO NM-110) refer to the respective 
codes of the OECD representative NMs (http://www.
oecd.org/science/nanosafety/).
The inorganic red pigment Fe2O3 (hematite), the two 
nanosized organic pigments Diketopyrrololpyrrol (DPP) 
Orange N, and Pigment Blue 15:1 (Cu-phthalocyanin) 
and graphite nanoplatelets (GraphEx®) were provided by 
BASF SE, Germany (cf. Arts et al. [79] for extensive char-
acterization data).
Finally, the micron-sized NC and benchmark material 
corundum (d50: 2.2 μm) was purchased from ESK (Elek-
troschmelzwerk Kempten, Germany) and the micron-
sized PC quartz dust DQ12 (d50: 2.1  μm) from DMT 
GmbH & Co. KG (Germany).
Preparation of test material suspensions
All test materials were suspended in the cell culture 
medium (F-12K; Biochrom GmbH, Germany) and, for 
H2O2 determination, in Krebs-Ringer phosphate glu-
cose (KRPG) buffer. KRPG buffer (pH value 7.3–7.4) is a 
physiological salt solution that contains 129  mM NaCl, 
4.86 mM KCl, 1.22 mM CaCl2, 15.8 mM NaH2PO4, and 
5.5  mM glucose. In preparing the test material suspen-
sions, approx. 1  mg of the dry-powder test items was 
weighed into a 15  mL polypropylene tube (Greiner, 
Germany). The necessary amount of fluid (3–10  mL) 
was added to achieve final maximum concentrations of 
180  μg/mL F-12K medium or 360  μg/mL KRPG buffer, 
the latter being diluted twofold under testing condi-
tions. Test items delivered as liquid suspensions (i.e., 
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SiO2.naked and its surface functionalized variants and 
both ZrO2 NMs) were diluted accordingly. Upon sus-
pension and/or dilution, the tubes were briefly vortexed 
to remove particles from the vessel wall. Afterwards, the 
preparations were ultrasonicated for 10  s using a probe 
adjusted to 50 W (Vibra Cell™, Sonics & Materials, USA). 
This step was recognized as indispensable to separate 
aggregates of the micron-scaled controls quartz DQ12 
and corundum, and it was also included in preparing the 
dry-powder and liquid test items.
Due to poor dispersibility, the general protocol for test 
material preparation was adapted for the following test 
materials: SiO2 NM-200 and NM-203, which were deliv-
ered strongly agglomerated, were treated with an ultra-
sonic probe on ice (5× for 1  min, each). Pigment Blue 
15:1 and graphite nanoplatelets required pre-wetting in 
0.5 % (v/v) ethanol. For this purpose, a stock dispersion 
of 2.56 mg/mL (with the further addition of 0.05 % (w/v) 
bovine serum albumin in the case of Pigment Blue 15:1 to 
warrant dispersion) was prepared by 10-min bath ultra-
sonication (Sonorex, DT106, Bandelin Electronic, Berlin, 
Germany). Fe2O3 and DPP Orange N were bath ultrason-
icated (2× for 10  min, each) upon dispersion in double 
distilled water.
All test material suspensions were prepared shortly 
before in  vitro application. For LDH, GLU and TNF-α 
determination, the suspensions were serially diluted with 
F-12K medium to achieve test concentrations of 22.5, 
45, 90, and 180 μg/mL. For H2O2 determination, the test 
material suspensions were first diluted in KRPG buffer 
to a twofold of these concentrations (i.e., 45–360 μg/mL) 
since the Amplex red assay begins with a 1:1 dilution step 
(cf. “H2O2 formation” section). Accordingly, all four end-
points were generally assessed at final test material con-
centrations of 22.5-180  μg/mL. As exceptions from this 
rule, the highly bioactive ZnO NM-111 was tested for 
LDH and TNF-α at 2.8, 5.6, 11.2 and 22.5 μg/mL (but up 
to 180 μg/ml for GLU and H2O2). For technical reasons, 
ZrO2.acrylate was assessed at 35–283  μg/mL. For all 
tests, material-free vehicle controls were carried out.
Particle size distribution in water, F‑12K medium or KRPG 
buffer
The particle size distribution and agglomerating prop-
erties of the test materials suspended in water were 
assessed by particle tracking in the supernatant (detec-
tion range: 30–1000  nm) and by inspection of the 
agglomerates (detection range:  >0.7  μm). All test mate-
rial suspensions were diluted as necessary to achieve 
optimal measurement conditions of 5  ×  108 particles/
mL. Laser illumination combined with tracking analysis 
allowed detecting nanoparticles down to a concentra-
tion of 1 × 108/mL: The size distribution of the dispersed 
particles was evaluated with a NanoSight LM 10 instru-
ment (Malvern Instruments, England) equipped with 
a green (532  nm) or blue (405  nm) laser and using the 
accompanying NTA software 2.1–2.3. Agglomerated 
and gravitationally settled particles were recorded at 
the bottom of the culture vessels (96 well plates) using 
an inverted microscope (Axiocert 40C, Zeiss, Germany) 
equipped with phase contrast optics (10× or 20× objec-
tives). Digital images (Axiocam C3, Zeiss, Germany) 
were taken after 16 h in the absence (cell-free controls) or 
presence of cells to document particle uptake under test-
ing conditions [91].
Additionally, the test materials were analysed as 
described above suspended in 360  μg/mL KRPG buffer 
or 180 μg/mL F-12K medium. The incubation conditions 
were identical to the ones applied during in  vitro test-
ing, apart from the fact that no NR8383 cells were pro-
vided. Again, the suspensions were diluted as necessary 
to achieve optimal measurement conditions.
Preparation of the NR8383 test system
Rat NR8383 cells [60, 61] were originally purchased from 
ATCC (USA) and cultured in F-12K medium supple-
mented with 2  mM glutamine, penicillin/streptomycin 
(100 U/10 mg/mL; and 15 % (v/v) fetal calf serum (FCS; 
all from PAN Biotech GmbH, Germany). Cells were 
grown in 500 mL flasks (Greiner, Germany) under stand-
ard cell culture conditions (37 °C; 5 % CO2) and passaged 
once a week. For the in  vitro tests, cells were detached 
from the substrate by mechanical agitation, dispersed by 
pipetting, seeded into 96-well plates at 3 × 105 live cells 
per well and incubated in F-12K medium supplemented 
with 5  % FCS for 24  h. For test material application, 
supernatants were withdrawn, and test material-contain-
ing phenol red-free F-12K medium (Biochrom GmbH, 
Germany), supplemented with 2 mM glutamine and 100 
U/100  μg/mL penicillin/streptomycin, was applied onto 
the cells. To correct for test material-specific adsorption 
and/or scattering of light, cell-free NM-containing con-
trols were included in all test runs for all dilution steps. 
Cells were incubated with particles for 16 or 1.5  h. For 
the determination of LDH, GLU, and TNF-α release, cell 
culture supernatants were sampled after 16 h of incuba-
tion. In a parallel approach, supernatants were sampled 
after 1.5 h of incubation to assess H2O2 formation.
Lactate dehydrogenase and glucuronidase
To measure the amount of LDH and GLU released from 
the treated NR8383 cells, cell culture supernatants were 
harvested and centrifuged (10  min, 200  g) to remove 
cell debris. From each well, 50  μL was incubated with 
LDH reaction mix (Roche Cytotoxicity Kit; Roche, Ger-
many) and evaluated as described by the manufacturer. 
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Measurements were corrected for cell free-adsorption 
and normalized to the PC value (set to 100 %) obtained 
from NR8383 cells lysed with 0.1 % Triton X-100 (Sigma 
Aldrich, Germany). To measure GLU activity, 50 µL 
of the supernatant was incubated at 37  °C with 100  μL 
0.2 M sodium acetate buffer (pH 5) containing 13.3 mM 
p-nitrophenyl-d-glucuronide (Sigma Aldrich, Germany) 
and 0.1 % Triton X-100 [50]. The reaction was terminated 
after 2  h by addition of 100  μL 0.2  M NaOH (Merck 
KGaA, Germany). Optical density (OD) was measured at 
405 nm in a plate photometer (Tecan 200Pro, Tecan, Ger-
many); values were corrected for cell free-adsorption and 
normalized to the PC value (set to 100 %) again obtained 
from NR8383 cells lysed with 0.1 % Triton X-100.
Bioactive tumour necrosis factor alpha
To measure the bioactive TNF-α released from the 
treated NR8383 cells, cell culture supernatants were 
centrifuged and analysed using the L929 cytolysis test 
described by Desch et  al. [92]. Briefly, 50  μL super-
natant was pipetted onto 80  % confluent L929 mouse 
fibroblasts (ATCC, USA) in the presence of actinomy-
cin D (Sigma Aldrich, Germany). After 24  h, the L929 
cells were washed with phosphate buffered saline (PBS; 
Biochrom GmbH, Germany), stained with 0.5  % crys-
tal violet (Sigma Aldrich, Germany), washed extensively 
with PBS, and lysed in an acidic mixture of citrate-buff-
ered 50  % ethanol (Carl Roth GmbH, Germany). OD 
was measured at 570 nm, and results were expressed as 
L929 fibroblast lysis relative to non-treated medium con-
trols, which were set to 0 %. Additionally, the L929 cells’ 
responsiveness to TNF-α was controlled using a TNF-α 
standard (510-RT; Bio-Techne, Germany), and the upper-
most value (1000 pg TNF-α/mL) was set to 100 %. As an 
additional PC, the TNF-α-forming capacity of NR8383 
cells was confirmed by stimulation with lipopolysaccha-
ride (LPS; 0.1 μg/mL, Sigma Aldrich, Germany). Finally, 
the direct effects of the test materials on L929 cells were 
assessed using 50 µL of the supernatants from cell-free 
NM-containing wells.
H2O2 formation
H2O2 synthesized by NR8383 cells and released into 
the supernatant was quantified in the Amplex red assay 
by measuring the formation of resorufin. All chemicals 
used within this assay were supplied by Sigma Aldrich 
(Germany). NR8383 cells were seeded in 96-well micro-
titre plates at a density of 3  ×  105 cells/well and incu-
bated under standard cell culture conditions. After 24 h, 
the medium was replaced by 100  μL of the test materi-
als suspended in KRPG buffer. Immediately after incu-
bation with the test material suspensions, 100  μL/well 
of a freshly prepared reaction mix containing 0.1  mM 
Ampliflu, 2 mM NaN3, and 2 U/mL horseradish peroxi-
dase was added and incubated at 37 °C for 90 min. KRPG 
buffer was used as NC and 180  μg/mL zymosan as PC. 
Accuracy of the reactions was controlled with a 30  μM 
H2O2 standard concentration prepared from a 30 % stock 
solution freshly prepared from a 30 % H2O2 stock solu-
tion. OD was measured at 570 nm and 620 nm (reference 
value), corrected for background absorbance of cell free-
particle controls and converted into absolute concentra-
tions of H2O2 using the molar extinction coefficient of 
resorufin (54,000 L × mol−1 × cm−1).
Statistical analysis
In vitro data were generated in triplicates and at least 
three independent repetitions were carried out. Data 
were expressed as mean ±  standard deviation (SD) and 
analysed with Graph Pad Prism software (Version 6; 
GraphPad Software Inc., USA). To test for significance, 
test values were compared to those from non-treated 
vehicle controls using 2-way ANOVA and Dunnett’s post 
hoc multiple comparison test. Test results with p ≤ 0.05 
were assessed as significant (*). Additionally, the signifi-
cance of results was assessed by comparison to the effects 
elicited by equal particle concentrations of the negative 
benchmark material corundum. Finally, the concordance 
of the in vitro NR8383 AM assay results and the outcome 
of in  vivo inhalation studies was assessed using Cooper 
statistics [93].
Prediction model
A prediction model was developed to enable using the 
data from the in  vitro NR8383 AM assay to distinguish 
active from passive NMs.
Test material categorization as ‘active’ or ‘passive’ using STIS 
data
The primary (‘gold standard’) distinction between active 
and passive (nano)materials was based upon in  vivo rat 
STIS data that were available for the test materials [10, 
11, 79–82]. Only for AlOOH, the available in vivo inhala-
tion data were not recorded after 5-day inhalation expo-
sure to rats (i.e., following the STIS test protocol), but in 
a 28-day sub-acute inhalation study conducted in accord-
ance with OECD TG 412 [58].
NOAECs  <  10  mg/m3 that were assigned on account 
of any adverse treatment-related inflammatory reac-
tion elicited in the rat upon 5-day inhalation exposure of 
the given NM under the testing conditions of the well-
defined STIS resulted in test material assignment as 
active. This definition considered any inflammatory effect 
recorded by haematology, BALF evaluation, and/or lung 
histopathology. Test materials were assigned as passive if 
no treatment-related findings were recorded at 10 mg/m3 
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or even higher concentratons in the STIS. Accordingly, 
their NOAEC was 10 mg/m3 or higher (indicated as ‘≥’ 
in Table 3). Since AlOOH was tested for 28 days (i.e., for 
four consecutive 5-day exposure periods), the NOAEC 
that Pauluhn [58] recorded for this material (i.e., 3  mg/
m3) was converted to a 5-day NOAEC by multiplying it 
by a factor of four (i.e., 12 mg/m3) [94].
The recorded STIS NOAECs and lowest-observed-
adverse-effect concentrations (LOAECs) for those mate-
rials that elicited inflammatory effects in at least one test 
group are provided in Table 3. Based thereupon, quartz 
DQ12, TiO2 NM-105, ZnO NM-111, all CeO2 test mate-
rials, as well as the three SiO2 NMs without surface 
functionalization (i.e., SiO2.naked, SiO2 NM-200 and 
NM-203) were categorized as in vivo active, and all other 
test materials were categorized as in vivo passive (cf. “In 
vitro studies and test material assignment as active or 
passive” section for further details on the available in vivo 
data). The prediction model for the in vitro NR8383 AM 
assay was conceived to provide the best possible correla-
tion to this in vivo categorization.
Determination of in vitro lowest‑observed effect 
concentration
The data obtained for all four in  vitro endpoints (or 
‘parameters’, i.e., LDH, GLU, TNF-α, H2O2) were 
recorded separately for all test materials. As described 
in “Statistical analysis” section, the significance of indi-
vidual test results was assessed by comparing them both 
to the results obtained for the non-treated cell controls 
(Table  3) and the negative benchmark material corun-
dum (Additional file  1: Table S1). The lowest dose at 
which significant effects were recorded for a given end-
point-specific test result was termed in vitro LOAEC.
Definition of in vitro threshold value
Consistent with the ‘vector model’ described by Rehn 
et  al. [54, 55], in which the in  vitro dosages were set to 
cover the mass-based in vivo concentration range that is 
likely to be taken up by rat AMs (cf. “Background” sec-
tion), a mass-based dose metric was primarily used both 
for the in  vitro testing and to assess the in  vivo STIS 
findings. However, the effects of NMs on AMs may not 
be directly related to the particle mass. While the dose 
metric of particle volume appears relevant to determine 
AM overloading [23, 24], at test material concentrations 
below the threshold for volume overload, the effects of 
NMs on AMs appear to be mainly conveyed by the parti-
cle surface. Accordingly, surface area has been suggested 
as a more appropriate dose metric for the in vitro testing 
of NMs [95–99].
To convert the mass-based test material concentra-
tions into surface area-based concentrations, the applied 
mass concentrations (μg/mL) were multiplied with the 
respective test material’s surface area (m2/g) as assessed 
by the method of Brunauer Teller and Emmett (BET). 
The BET surface area is an approximation of the actual 
surface area of primary particles and/or agglomerates to 
the biologically accessible surface [100]. This conversion 
resulted in the dose metric of particle surface area per 
volume (mm2/mL).
For the in  vitro distinction between active and pas-
sive test materials, a threshold value of 4000  μm2 per 
NR8383 cell (mean diameter: 12.5 μm) was set at the cel-
lular level (see also “Test protocol, prediction model, and 
threshold values” section for explanation). This value cor-
responds to 1200 mm2 particle surface area per 3 × 105 
cells which actively gather particles at the bottom of a 
well of a 96-well culture plate (equivalent to 3600 mm2/
cm2 cell culture surface area). As the cell culture wells 
are filled with 200 μL culture medium the above thresh-
old value amounts to 6000 mm2/mL and this dimension 
was used to convert applied test material concentra-
tions (expressed in μg/mL) into the in vitro LOAEC val-
ues as shown in Table 3. Any significant in vitro LOAEC 
recorded below this threshold value was interpreted as 
biologically relevant, i.e., NM-specific cellular effect. 
By contrast, a significant in  vitro LOAEC that was only 
recorded at a test material concentration exceeding the 
threshold was interpreted as unspecific and being caused 
by cellular overload, but not by particle-specific toxicity.
In vitro definition of ‘active’ and ‘passive’ test materials
To strengthen the robustness of the assay and to rule out 
incidental or borderline reactions by founding assign-
ments on one affected endpoint alone, NMs were only 
assigned as active if significant in  vitro LOAECs below 
the threshold value of 6000 mm2/mL were recorded for 
at least two of the four in vitro endpoints (e.g., elevated 
LDH and TNF-α). The occurrence of no or only one sig-
nificant in  vitro LOAEC below the threshold value of 
6000  mm2/mL resulted in NM assignment as passive. 
(Nevertheless, the occurrence of one significant finding 
alone may be noteworthy for the further investigation of 
specific mechanisms of toxicity.)
Results
Test material characterization
Table 1 presents the test materials’ primary particle size 
(PPS; determined by transmission electron microscopy 
(TEM) or scanning electron microscopy (SEM)), BET 
surface area, and their particle size distribution (mean or 
modal values, d50 and d90) in water, KRPG buffer or F-12K 
medium. In general, particle sizes measured with track-
ing analysis in H2O were larger than the corresponding 
PPS. This was assessed as being either an indication for 
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agglomeration and/or the material-dependent detection 
limit of the tracking analysis method.
For most test materials, the numbers of particles dis-
persed in KRPG buffer or F-12K medium after 16-h 
incubation underscored the detection limit for reliable 
tracking analysis (indicated as ‘not detectable’ in Table 1). 
Only for SiO2.naked, SiO2.amino, SiO2.phosphate, SiO2 
NM-203, the inorganic pigment Fe2O3, and the two 
organic pigments DPP Orange N and Pigment Blue 
15:1, measurable numbers of dispersed particles were 
recorded in KRPG buffer or F-12K medium at the end of 
the incubation period (Table 1):
Despite their small size and low light scattering prop-
erties, colloidal SiO2.naked and its negatively charged 
surface functionalized variants SiO2.amino and SiO2.
phosphate were observable with tracking analysis in H2O, 
and particle sizes matched the upper PPS. Under testing 
conditions, i.e., in KRPG buffer and in F-12K medium, 
Table 1 Primary characterisation of the test materials and agglomeration in biological fluids
Primary particle size and BET surface area values were taken from Landsiedel et al. [11], Kroll et al. [17], Singh et al. [87, 88], and Rasmussen et al. [89, 90]
Form of the as-supplied test materials: Powder (P); Suspension (S)
Size measurements of the NM preparationss were carried out with NanoSight tracking analysis in double destilled water, in KRPG buffer, and F-12K culture medium; 
not detectable: not detectable due to low or missing particle concentration
Conc.: Concentration of nanoparticles as indicated by the NanoSight software; values were multiplied by the dilution factor
Test materials Size Surface area Form Size in H2O Size in KRPG Size in F‑12 K Conc. in F‑12K
SEM, TEM [nm] BET [m2/g] [nm] [nm] [nm] [Particles/mL]
TiO2 NM‑105 28 47 P d50 167
d90 246
Not detectable Not detectable Not detectable
ZnO NM‑111 82 15 P Not detectable Not detectable Not detectable Not detectable
Nano‑CeO2 40 33 P d50 159
d90 263
Not detectable Not detectable Not detectable
Al‑doped CeO2 2–160 46 P d50 132
d90 189
Not detectable Not detectable Not detectable
CeO2 NM‑211 10–20 66 P d50 130
d90 199
Not detectable Not detectable Not detectable
CeO2 NM‑212 10–20 27 P d50 136
d90 195
Not detectable Not detectable Not detectable







SiO2.PEG 8–45 200 S d50 54
d90 83
Not detectable Not detectable Not detectable














SiO2 NM‑200 10–20 189 P d50 129
d90 177
Not detectable Not detectable Not detectable




Not detectable Not detectable
AlOOH 40 47 P d50 163
d90 243
Not detectable Not detectable Not detectable
BaSO4 NM‑220 25 41 P d50 86
d90 130
Not detectable Not detectable Not detectable







ZrO2.TODA 3–15 117 S d50 77
d90 113
Not detectable Not detectable Not detectable
ZrO2.acrylate 9 117 S d50 172
d90 244
Not detectable Not detectable Not detectable














Graphite nanoplatelets <30 μm (flakes) 74 P Not detectable Not detectable Not detectable Not detectable
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particle sizes of these materials only slightly increased, 
gravitational settling was minimal, and only few agglom-
erates became visible at the bottom of the culture dish. 
Particle concentrations in F-12K medium ranged from 
1.0 × 1011 particles/mL for SiO2.phosphate to 2.9 × 1011 
particles/mL for SiO2.amino. By contrast, the neutral 
SiO2.PEG completely agglomerated in all media and no 
dispersed nanoparticles were detectable in either KRPG 
buffer or F-12K medium.
Unlike the colloidal SiO2 NMs, the dry-powder amor-
phous SiO2, i.e., precipitated SiO2 NM-200 and pyro-
genic SiO2 NM-203, required extensive ultrasonication to 
destroy large agglomerates. Nevertheless, dispersed SiO2 
NM-200 or NM-203 nanoparticles were not detectable by 
tracking analysis in F-12K medium at the end of the incu-
bation period (but in KRPG buffer for SiO2 NM-203). For 
both dry-powder SiO2 test items, gravitational settling 
occurred that was more pronounced than for the colloi-
dal SiO2 NMs.
Within 16 h, low, but detectable amounts of dispersed 
particles of inorganic Fe2O3 or organic DPP Orange N 
were observed in the F-12K supernatant with mean par-
ticle sizes of 113 and 89 nm, respectively. By comparison, 
the PPSs were 15 nm for Fe2O3 and 30–400 × 10–50 nm 
for DPP Orange N. Even though slight colourations 
remained in the medium after agglomerate sedimenta-
tion, this could be corrected for using cell-free controls 
and, therefore, did not affect the OD measurements. Par-
ticle concentrations in F-12K medium were 2.7 × 108 for 
Fe2O3 and 1.3 × 108 for DPP Orange N, i.e., by a factor of 
103 lower than the concentrations recorded for the dis-
persed colloidal SiO2 NMs.
Pigment Blue 15:1 could be dispersed in H2O by ultra-
sonication (180 μg/mL resulted in 5 × 1010 particles/mL; 
d50:191  nm as compared to a PPS of 17  nm). However, 
less than 5 % of that particle number concentration were 
observed in F-12K medium after 16 h incubation (180 μg/
mL resulted in 2.1 ×  109 particles/mL; d50: 173  nm) in 
spite of the addition of 0.05 % (w/v) bovine serum albu-
min during ultrasonication. The vast majority of this 
nanosized pigment formed blue agglomerates.
Cellular uptake of the test materials
Agglomerated particles settled to the bottom of the cul-
ture vessel where they were visible with phase contrast 
optics. As a rule, the test materials agglomerated and set-
tled gravitationally within the 16-h incubation period. 
This settling occurred within minutes for corundum, 
within less than 1  h for quartz DQ12, 3–4  h for ZrO2.
TODA, 6 h for ZrO2.acrylate, or by the end of the 16 h 
incubation period for TiO2 NM-105 and all four CeO2 
NMs. Further as a rule, up to the highest test mate-
rial concentration of 180  μg/mL, all test materials were 
completely engulfed by the NR8383 AMs (that are pre-
sent at the bottom of the cell culture vessels) by the 
end of the 16-h incubation period (cf. Fig.  1 for phase-
contrast images of settled particles and test material-
laden NR8383 AMs for corundum, quartz DQ12, TiO2 
NM-105, CeO2 NM-212, SiO2.naked, BaSO4 NM-220, 
DPP Orange N, and graphite nanoplatelets).
As exceptions to this rule, additional and specific 
observations were made for the following materials. 
Whereas complete cellular uptake was recorded for 
quartz DQ12 up to test concentrations of 90  μg/mL, 
many particles were visible outside deteriorated cells at 
180  μg/mL underlining the pronounced cytotoxic effect 
of this material. AlOOH formed branched agglomerates 
under culture conditions which settled as a fluffy layer. 
For the different types of CeO2 NMs, cellular uptake was 
complete up to a concentration of 90  μg/mL, whereas 
very few agglomerates remained between the NR8383 
cells at 180 μg/mL. Graphite nanoplatelets have a strong 
light absorbance. Nevertheless this carbonaceous NM 
could be measured colourimetrically up to a concen-
tration of 180  μg/mL since the substance precipitated. 
Although largely ingested by NR8383 macrophages, 
some large flocs of graphite nanoplatelets were not fully 
internalised, but were contacted by surrounding cells.
In conclusion, for most test materials, complete cellular 
uptake was recorded by the end of the incubation period 
at all tested concentrations. Only for SiO2.naked, SiO2.
amino and SiO2.phosphate, relevant proportions had not 
sedimented within 16  h (and hence could not be taken 
up by the AMs). Further, for graphene nanoplatelets, that 
did sediment, the highest test substance concentration 
was not fully internalized by the cells.
In vitro studies and test material assignment as active or 
passive
In the following, for each test material, the in vitro data 
are presented and evaluated to assign the material as 
either passive or active, and this in  vitro assignment is 
directly compared to the outcome of the corresponding 
available in vivo studies and the resulting in vivo catego-
rization as active or passive test materials.
Table  2 provides an overview of the data collected 
in the in  vitro NR8383 AM assay determining extracel-
lular release of LDH, GLU, TNF-α, and H2O2 listing all 
endpoint-specific data recorded at all test material con-
centrations (expressed in mass per volume metrics; i.e. 
µg/mL). In further processing these data, Table  3 pre-
sents the endpoint-specific significant in  vitro LOAECs 
recorded for each test material, expressing these values 
both in mass per volume metrics and in relation to the 
BET surface area (i.e., mm2/mL). Thereby, Table 3 reveals 
whether significant effects occurred below the threshold 
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value of 6000 mm2/mL, and if so, how many parameters 
were significantly affected below the threshold for a given 
test material. Based thereupon, Table 3 further provides 
the in  vitro NM assignments as either active or passive 
with contrasting juxtaposition to the STIS NOAECs, 
LOAECs and in vivo categorizations as active or passive.
For a better overview, Tables  2 and 3, just as the fol-
lowing subsections of “In vitro studies and test material 
assignment as active or passive”, are subdivided into the 
following sections: First, the data for the NC and PC are 
provided, i.e., corundum (Al2O3) and quartz DQ12. Next, 
the data for the seven metal oxide NMs that were iden-
tified as active in vitro are presented, i.e., TiO2 NM-105, 
ZnO NM-111, and all four tested CeO2 NMs. This is 
followed by the data recorded for the amorphous SiO2 
NMs. The subsequent section presents the data for the 
four metal oxide and metal sulphate NMs that were iden-
tified as passive in  vitro, i.e., AlOOH, BaSO4 NM-220, 
Fe2O3, and both surface-functionalized ZrO2. The final 
two sections present the data recorded for the two nano-
sized organic pigments and graphite nanoplatelets.
Corundum
In vitro, corundum is assigned as  passive Corundum 
induced very slight dose-dependent increases of LDH, 
TNF-α and H2O2, all of which were not significantly dif-
Fig. 1 Test material sedimentation and uptake by NR8383 rat alveolar macrophages. A Corundum; B Quartz DQ12; C TiO2 NM‑105; D CeO2 NM‑212; 
E SiO2.naked; F BaSO4 NM‑220; G DPP Orange N; H Graphite nanoplatelets. Phase contrast micrographs show settled particles at the bottom of cell‑
free wells in 96‑well plates (a1–h1 on the left side of the individual images) and corresponding particle‑laden NR8383 cells at the end of the 16‑h 
incubation period with the same particle concentration a2–h2 on the right side of the individual images). Note that the uptake of particles (loaded 
with 90 μg/mL) appears complete as viewed by light microscopy, except for SiO2.naked (loaded with 22.5 μg/mL), where settled particles are hardly 
visible
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Table 2 Effects of  the negative control corundum, the positive control quartz DQ12, and  the 20 test materials on  the 
NR8383 cells
Test material μg/mL LDH GLU TNF‑α ROS/H2O2
[% of PC] [% of PC] [% standard]a [% of PC]
Corundum 0 18.5 ± 2.7 3.7 ± 0.6 0.0 ± 0.0 2.7 ± 1.7
22.5 17.3 ± 3.6 3.7 ± 0.6 14.3 ± 4.8 1.0 ± 0.3
45 20.2 ± 3.1 4.2 ± 0.8 14.7 ± 5.7 1.4 ± 0.8
90 23.2 ± 2.5 4.5 ± 0.2 16.5 ± 7.1 1.9 ± 0.9
180 25.8 ± 2.5 4.7 ± 0.5 26.0 ± 5.1 2.2 ± 1.3
Quartz DQ12 0 20.5 ± 1.3 3.7 ± 0.6 0.0 ± 0.0 2.7 ± 1.7
22.5 18.5 ± 2.6 4.2 ± 1.7 8.3 ± 5.1 3.6 ± 2.7
45 31.3 ± 6.0 6.4 ± 1.5 47.6 ± 12.1* 3.4 ± 2.6
90 66.4 ± 6.3* 15.0 ± 3.4* 80.9 ± 10.4* 4.6 ± 2.3
180 95.4 ± 5.2* 31.7 ± 4.9* 95.8 ± 1.4* 5.7 ± 3.8
TiO2 NM‑105 0 18.0 ± 2.2 4.3 ± 3.5 0.0 ± 0.0 4.9 ± 4.3
22.5 14.0 ± 2.9 3.5 ± 0.9 19.2 ± 17.2 4.9 ± 4.3
45 26.2 ± 6.1 5.4 ± 1.7 25.8 ± 16.9 5.4 ± 4.9
90 53.6 ± 5.9* 11.5 ± 1.7* 55.4 ± 7.6* 5.0 ± 3.1
180 69.2 ± 1.1* 18.6 ± 0.7* 59.6 ± 6.6* 4.6 ± 4.8
ZnO NM‑111b 0 27.4 ± 1.4 4.2 ± 2.5 0.0 ± 0.0 0.3 ± 0.2
2.8/22.5 34.4 ± 1.4 4.1 ± 2.0 18.5 ± 5.0 0.0 ± 0.1
5.6/45 36.7 ± 1.1* 7.7 ± 0.9 19.1 ± 0.5 0.3 ± 0.5
11.3/90 39.1 ± 1.7* 18.2 ± 8.6* 13.2 ± 2.1 0.4 ± 0.6
22.5/180 127.0 ± 2.7* 19.9 ± 4.6* 89.1 ± 1.4* 0.3 ± 0.7
nano‑CeO2 0 25.0 ± 2.9 5.2 ± 0.4 0.0 ± 0.0 1.3 ± 0.0
22.5 18.5 ± 5.1 4.2 ± 0.2 20.5 ± 9.8 1.3 ± 0.2
45 28.4 ± 3.3 4.5 ± 0.1 35.8 ± 23.9* 1.2 ± 0.5
90 45.1 ± 2.1* 5.4 ± 0.2 89.3 ± 10.6* 2.8 ± 1.0
180 74.3 ± 9.3* 9.8 ± 0.5* 96.2 ± 5.3* 4.7 ± 1.1
Al‑doped CeO2 0 25.0 ± 2.9 5.2 ± 0.4 0.0 ± 0.0 1.3 ± 0.0
22.5 26.0 ± 8.4 5.0 ± 0.1 64.9 ± 35.2* 3.1 ± 0.1
45 56.5 ± 11.2* 8.6 ± 0.8 84.7 ± 14.1* 3.2 ± 0.5
90 84.1 ± 15.0* 19.8 ± 1.3* 89.8 ± 9.9* 4.2 ± 1.5
180 91.1 ± 14.7* 25.0 ± 0.3* 88.4 ± 12.6* 5.7 ± 0.5
CeO2 NM‑211 0 25.0 ± 2.9 5.2 ± 0.4 0.0 ± 0.0 1.3 ± 0.0
22.5 26.5 ± 8.5 6.0 ± 0.1 70.8 ± 11.1* 0.6 ± 0.9
45 38.9 ± 7.8 5.7 ± 0.2 65.4 ± 13.3* 0.3 ± 0.7
90 56.5 ± 7.0* 6.7 ± 0.2 75.0 ± 17.2* 2.7 ± 1.2
180 75.0 ± 7.1* 9.9 ± 0.1* 85.6 ± 15.6* 4.4 ± 1.7
CeO2 NM‑212 0 25.0 ± 2.9 5.2 ± 0.4 0.0 ± 0.0 1.3 ± 0.0
22.5 17.9 ± 7.8 4.9 ± 0.4 63.8 ± 29.4* 1.8 ± 0.8
45 29.2 ± 12.0 6.0 ± 2.2 66.7 ± 26.3* 1.1 ± 2.1
90 45.7 ± 14.6* 5.4 ± 0.2 76.9 ± 22.0* 2.9 ± 0.2
180 69.0 ± 16.6* 9.9 ± 0.8* 88.5 ± 10.7* 1.8 ± 0.5
SiO2.naked 0 19.9 ± 1.2 2.7 ± 2.0 0.0 ± 0.0 3.7 ± 2.1
22.5 40.5 ± 2.6* 5.0 ± 1.2 79.6 ± 3.0* 4.6 ± 2.9
45 87.6 ± 9.8* 14.7 ± 3.7* 93.4 ± 5.7* 10.7 ± 3.8*
90 100.1 ± 5.8* 24.6 ± 4.5* 77.3 ± 30.7* 13.9 ± 1.6*
180 83.8 ± 19.0* 25.8 ± 3.7* 65.0 ± 33.2* 14.1 ± 2.3*
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Table 2 continued
Test material μg/mL LDH GLU TNF‑α ROS/H2O2
[% of PC] [% of PC] [% standard]a [% of PC]
SiO2.PEG 0 19.9 ± 1.2 2.7 ± 2.0 0.0 ± 0.0 3.7 ± 2.1
22.5 22.8 ± 5.2 3.1 ± 0.6 26.2 ± 0.9 1.5 ± 4.3
45 30.5 ± 7.0 3.5 ± 1.1 26.2 ± 2.4 6.7 ± 4.1
90 69.9 ± 7.9* 10.8 ± 2.4* 61.6 ± 6.4* 10.2 ± 5.7
180 87.8 ± 7.8* 24.4 ± 4.5* 91.2 ± 4.4* 14.6 ± 6.8*
SiO2.amino 0 19.9 ± 1.2 2.7 ± 2.0 0.0 ± 0.0 3.7 ± 2.1
22.5 22.0 ± 1.8 3.0 ± 0.5 44.4 ± 3.8* 4.4 ± 1.8
45 70.4 ± 2.3* 8.2 ± 1.5* 99.1 ± 1.1* 5.5 ± 3.0
90 96.2 ± 13.1* 17.9 ± 5.4* 99.1 ± 1.1* 6.6 ± 3.5
180 99.7 ± 12.2* 25.8 ± 8.4* 98.3 ± 0.8* 13.0 ± 6.8*
SiO2.phosphate 0 19.9 ± 1.2 2.7 ± 2.0 0.0 ± 0.0 3.7 ± 2.1
22.5 16.6 ± 2.5 2.3 ± 0.5 25.0 ± 4.9 10.1 ± 4.2
45 29.8 ± 12.5 3.1 ± 0.3 19.9 ± 5.1 25.4 ± 6.2*
90 41.7 ± 21.7* 4.8 ± 1.4 53.0 ± 24.7* 37.2 ± 8.1*
180 48.6 ± 22.1* 7.3 ± 5.0* 78.7 ± 8.8* 36.8 ± 6.4*
SiO2 NM‑200 0 13.2 ± 1.2 4.8 ± 3.1 0.0 ± 0.0 0.4 ± 0.2
22.5 61.0 ± 2.1* 14.0 ± 5.6* 34.2 ± 25.0* 0.5 ± 1.5
45 90.8 ± 18.7* 26.6 ± 9.1* 46.2 ± 21.4* 0.5 ± 1.0
90 94.9 ± 13.8* 30.0 ± 4.8* 61.3 ± 22.6* 0.4 ± 1.0
180 88.2 ± 15.0* 23.5 ± 7.2* 72.0 ± 18.6* 0.3 ± 1.1
SiO2 NM‑203 0 13.2 ± 1.2 4.8 ± 3.1 0.0 ± 0.0 0.4 ± 0.2
22.5 83.9 ± 23.6 33.7 ± 6.4* 50.2 ± 16.7 0.7 ± 1.1
45 88.1 ± 13.8 34.3 ± 5.1* 49.8 ± 14.2 0.7 ± 1.2
90 85.3 ± 16.3* 30.1 ± 8.7* 50.0 ± 18.3 0.5 ± 0.8
180 86.7 ± 16.2* 32.2 ± 5.7* 64.4 ± 18.0* 0.3 ± 0.7
AlOOH 0 20.5 ± 1.5 3.6 ± 0.1 0.0 ± 0.0 0.3 ± 0.1
22.5 20.7 ± 1.6 3.5 ± 0.1 5.2 ± 0.3 0.0 ± 0.0
45 22.7 ± 1.6 3.3 ± 0.1 13.4 ± 1.8 0.0 ± 0.0
90 39.9 ± 0.1* 4.4 ± 0.1 14.8 ± 0.2 0.2 ± 0.3
180 61.5 ± 0.4* 6.6 ± 0.2 37.6 ± 4.1* 0.2 ± 0.2
BaSO4 NM‑220 0 22.2 ± 0.9 3.0 ± 0.3 0.0 ± 0.0 1.8 ± 2.0
22.5 24.0 ± 3.0 4.0 ± 0.3 0.0 ± 0.0 1.8 ± 2.1
45 27.5 ± 3.3 3.6 ± 0.4 0.0 ± 0.0 1.8 ± 2.4
90 30.2 ± 4.6 3.8 ± 0.3 0.0 ± 0.0 1.7 ± 2.0
180 37.1 ± 5.9 3.8 ± 0.4 2.5 ± 0.1 1.7 ± 1.8
Fe2O3 (hematite) 0 22.1 ± 1.9 1.2 ± 1.0 0.0 ± 0.0 2.0 ± 0.8
22.5 20.0 ± 0.6 1.6 ± 0.7 17.5 ± 4.2 3.1 ± 0.6
45 25.4 ± 5.4 2.1 ± 0.5 16.5 ± 0.4 3.5 ± 0.4
90 26.0 ± 0.6 2.2 ± 0.4 32.1 ± 10.3* 4.1 ± 0.6
180 25.6 ± 0.9 2.8 ± 0.5 64.3 ± 33.2* 4.0 ± 1.0
ZrO2.TODA 0 22.7 ± 3.5 2.8 ± 2.1 0.0 ± 0.0 1.1 ± 0.6
22.5 25.7 ± 3.5 2.9 ± 1.1 21.8 ± 3.9 1.8 ± 0.5
45 39.9 ± 7.9* 3.0 ± 1.1 21.8 ± 6.4 5.8 ± 1.6
90 70.2 ± 8.4* 5.4 ± 0.8 68.7 ± 15.5* 8.3 ± 1.4*
180 81.2 ± 12.8* 7.2 ± 0.2 87.9 ± 10.5* 8.0 ± 2.3*
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ferent from the non-treated controls. This lack of effects 
confirms the suitability of corundum as NC and as a nega-
tive benchmark material.
In vivo categorization confirms corundum passivity Pre-
vious rat STISs underlined the inert nature of respirable 
corundum particles (aerosol concentration 20  mg/m3; 
2-week exposure, 5 days/week; 5 h/day) [77]. Also in rat 
instillation studies, corundum proved to be a chemically 
inert particle which hardly elicited any pulmonary inflam-
matory or fibrogenic effects [101, 102]. However, high 
intratracheal instillation doses of 7.5 mg/rat lung [102] or 
5 mg/100 g body weight [103], which are both in the over-
load range, elicited BALF changes that mainly consisted 
of elevated polymorphonuclear neutrophil (PMN) counts. 
In line with these findings, the United States National 
Institute for Occupational Safety and Health (NIOSH) 
has set an occupational exposure limit (OEL) of 5 mg/m3 
for respirable corundum (summarized by Krewski et  al. 
[104]). Taken together, corundum is categorized as pas-
sive in vivo, which confirms in vitro passivity.
Quartz DQ12
In vitro, quartz DQ12 is assigned as active The in vitro 
macrophage toxicity of quartz DQ12 is well-known [54, 
105]. Quartz DQ12 induced dose-dependent releases of 
LDH, GLU, and TNF-α, significant well below the thresh-
old value of 6000  mm2/mL. Even though quartz DQ12 
hardly elicited any extracellular H2O2 formation, the find-
ings confirm its suitability as PC and results in quartz 
DQ12 assignment as active material.
In vivo categorization confirms quartz DQ12 activity In 
a rat 28-day sub-acute inhalation study, a NOAEC of 
0.1 mg/m3 was recorded for alpha-quartz (median particle 
size: 1.7 µm) [106]. Due to its progressive inflammatory, 
fibrogenic and genotoxic effects, micron-sized quartz 
DQ12 is widely used as a PC for in  vivo studies [102, 
107]. As PC, it was tested at one (high) concentration, 
each, in two rat 5-day STISs. At 25 mg/m3, quartz DQ12 
produced progressively severe effects over the 3-month 
post-exposure period [80] with similar findings recorded 
at 100 mg/m3 [81]. Generally, the results observed in the 
Table 2 continued
Test material μg/mL LDH GLU TNF‑α ROS/H2O2
[% of PC] [% of PC] [% standard]a [% of PC]
ZrO2.acrylate
c 0 22.7 ± 3.5 2.8 ± 2.1 0.0 ± 0.0 1.1 ± 0.6
35 29.6 ± 8.4 3.3 ± 1.2 25.3 ± 4.7 0.7 ± 2.1
70.5 49.0 ± 13.6* 4.9 ± 1.6 48.5 ± 5.5* 7.4 ± 0.5
141 73.9 ± 11.3* 11.7 ± 3.7* 90.5 ± 1.7* 15.2 ± 2.8*
283 80.8 ± 4.1* 19.7 ± 5.8* 90.8 ± 6.2* 22.5 ± 4.7*
DPP orange N 0 22.1 ± 1.9 1.2 ± 1.0 0.0 ± 0.0 2.0 ± 0.8
22.5 19.9 ± 1.9 1.8 ± 0.6 25.9 ± 16.5 1.0 ± 0.1
45 22.7 ± 1.9 2.3 ± 0.6 48.7 ± 37.7* 1.5 ± 0.4
90 25.7 ± 1.1 3.2 ± 0.4 66.0 ± 57.0* 2.2 ± 0.4
180 28.4 ± 0.5 5.3 ± 0.7 81.5 ± 30.9* 3.3 ± 1.3
Pigment blue 15:1 0 20.5 ± 1.3 4.2 ± 0.2 Not determined 0.2 ± 0.2
22.5 17.4 ± 3.1 6.0 ± 0.3 0.0 ± 0.0
45 20.0 ± 3.6 8.4 ± 3.5 0.0 ± 0.0
90 41.0 ± 7.2* 10.6 ± 0.6* 0.0 ± 0.0
180 88.0 ± 7.9* 21.9 ± 2.2* 0.0 ± 0.0
Graphite nanoplatelets 0 22.1 ± 1.9 1.2 ± 1.0 0.0 ± 0.0 2.0 ± 0.8
22.5 24.2 ± 2.6 2.6 ± 1.0 2.2 ± 2.9 1.4 ± 0.8
45 26.3 ± 1.9 3.3 ± 1.2* 8.4 ± 4.8 2.1 ± 1.2
90 29.9 ± 0.4 5.7 ± 1.9* 30.2 ± 17.2* 4.1 ± 2.0
180 37.8 ± 3.3 11.8 ± 2.5* 74.8 ± 9.4* 7.1 ± 1.3
To test for significance, test values were compared to those from non-treated vehicle controls using 2-way ANOVA with Dunnett’s post hoc multiple comparison test, 
and p ≤ 0.05 was assessed as significant (*)
a Measurements of TNF-α are expressed as L929 fibroblast lysis relative to non-treated medium controls, which were set to 0 %
b Due to its high bioactivity, ZnO NM-111 was tested for release of LDH and TNF-α at 2.8–22.5 μg/mL, whereas GLU and H2O2 formation were assessed at 22.5–180 μg/
mL
c For technical reasons, ZrO2.acrylate was assessed at 35–283 μg/mL
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STIS at the end of the post-exposure observation periods 
resembled those recorded in sub-chronic inhalation stud-
ies [108]: Macrophage, monocyte, PMN, and also lym-
phocyte counts were increased in the lung parenchyma 
and BALF, which coincided with elevated levels of total 
protein and enzyme activities [LDH, alkaline phosphatase 
(AP), γ-glutamyltransferase (GGT) and N-acetyl-glucosa-
minidase (NAG)]. Upon intratracheal instillation in rats, 
pulmonary fibrosis was observed even after bolus doses of 
only 0.15–0.3 mg [102, 109]. Such dosages may be reached 
under STIS conditions by aerosol concentrations that are 
far lower than 10 mg/m3. In conclusion, quartz DQ12 is 
categorized as active material, which confirms the in vitro 
assignment.
Active metal oxide NMs (TiO2, ZnO, CeO2)
In vitro, TiO2 NM‑105 is assigned as  active TiO2 
NM-105 elicited dose dependent increases of LDH, GLU, 
and TNF-α (significant in vitro LOAECs at 4230 mm2/mL, 
each), whereas H2O2 formation did not differ from the 
vehicle control. Since significant in vitro LOAECs below 
the threshold value of 6000 mm2/mL were recorded for 
3 of the 4 parameters, TiO2 NM-105 is assigned as active 
NM.
In vivo categorization confirms TiO2 NM‑105 activity In 
a number of different STISs assessing both coated and 
uncoated TiO2 NMs, pulmonary inflammatory changes 
were recorded, with a NOAEC for TiO2 NM-105 of <2 mg/
m3 and a LOAEC of 2 mg/m3. Most prominent findings 
were BALF increases in total cell count, PMNs, and AMs. 
Additionally, total protein and the activities of LDH, ALP, 
GGT, NAG were increased [10, 11, 81]. Based upon these 
in vivo STIS data, TiO2 NM-105 is categorized as active 
NM, which confirms the in vitro assignment.
ZnO NM‑111 is assigned as in vitro active ZnO NM-111, 
that is coated with triethoxycaprylylsilane, is a NM with 
a comparably small BET surface area of 15.1 m2/g. This 
material dissolves in acidic environments thereby shedding 
zinc ions [79]. Maximum cytotoxicity (release of LDH) 
was already observed at 22.5 μg/mL (significant in vitro 
LOAEC at 5.6 μg/mL, i.e., 84 mm2/mL), while the param-
eter GLU became significant at 90 μg/mL (1350 mm2/mL) 
and TNF-α induction was at its maximum between 22.5 
and 45 μg/mL (in vitro LOAEC 338 mm2/mL). TNF-α for-
mation was inhibited at higher concentrations due to pro-
gressive cell degradation. Extracellular H2O2 formation 
induced by ZnO NM-111 was in the same range as the 
concurrent vehicle control value. In parallel studies, the 
non-coated core material ZnO NM-110 was even more 
toxic than coated ZnO NM-111 for all parameters tested 
(data not shown). Since significant in vitro LOAECs below 
the threshold value of 6000 mm2/mL were recorded for 3 
of the 4 parameters, ZnO NM-111 (just as ZnO NM-110) 
is assigned as active NM.
In vivo categorization confirms ZnO NM‑111 activ‑
ity Coated ZnO NM-111 elicited extensive signs of 
inflammation in the BALF upon 5-day inhalation expo-
sure to 2.5 mg/m3 (NOAEC: 0.5 mg/m3). The most promi-
nent findings were increased total cell counts caused by 
invaded PMNs, lymphocytes, and monocytes [11]. Total 
protein concentration and enzyme activities (GGT, LDH, 
ALP and NAG) were increased as well, just as a number 
of inflammatory mediators, i.e., cytokine-induced neu-
trophil chemoattractant 1 (CINC-1, the rat homologue to 
IL-8), clusterin, cystatin C, granulocyte chemotactic pro-
tein 2 (GCP-2), and MCP-1. In a 14-day STIS, 8 mg/m3 
uncoated ZnO NM-110 (only this concentration tested) 
also elicited pulmonary inflammatory effects so that a 
14-day NOAEC < 8 mg/m3 was assigned to ZnO NM-110 
[110]. Based upon these in vivo STIS data, ZnO NM-111 
(just as ZnO NM-110) is categorized as active NM, which 
confirms the in vitro assignment.
All four CeO2 NMs (Al‑doped CeO2, nano‑CeO2, CeO2 
NM‑211, and  CeO2 NM‑212) are assigned as  in  vitro 
active All four types of CeO2 NMs dose-dependently 
increased LDH and GLU release. The in  vitro LOAECs 
recorded for LDH were significant and below the threshold 
value of 6000 mm2/mL for all four CeO2 NMs. Addition-
ally, for Al-doped CeO2, the in vitro LOAEC recorded for 
GLU was significant and below the threshold value. Evalu-
ation of these two parameters that indicate cell membrane 
damage resulted in the following ranking of cytotoxicity 
(when using the particle surface area-based LOAECs): 
Al-doped CeO2  >  CeO2 NM-212  >  nano-CeO2  >  CeO2 
NM-211. H2O2 formation was far less pronounced 
(and never significant), but also headed by Al-doped 
CeO2. Finally, the in vitro LOAECs recorded for TNF-α 
induction were significant and below the 6000  mm2/
mL threshold value for all four CeO2 NMs, albeit with a 
slightly different ranking, i.e., CeO2 NM-212 > Al-doped 
CeO2  >  CeO2 NM-211  =  nano-CeO2. Accordingly, the 
findings indicate different biological activities and poten-
cies of in vitro cellular effects of the four tested CeO2 NMs 
with Al-doped CeO2 and CeO2 NM-212 eliciting more 
pronounced effects than nano-CeO2 or CeO2 NM-211. 
Since significant in  vitro LOAECs below the threshold 
value of 6000  mm2/mL were consistently recorded for 
the two parameters LDH and TNF-α (and additionally for 
GLU in the case of Al-doped CeO2), all four CeO2 NMs 
are assigned as active.
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In vivo categorization confirms activity for all four CeO2 
NMs All four CeO2 NMs induced a pronounced tran-
sient inflammation at 0.5 mg/m3, and effects increased at 
higher doses up to 25 mg/m3 [11, 111]. Three days post-
exposure, relative PMN fractions in the BALF increased to 
76 and 79 % for Al-doped CeO2 and nano-CeO2, respec-
tively, and concomitantly, the BALF total protein levels 
were elevated [11]. For all four CeO2 NMs, a NOAEC of 
<0.5 mg/m3 was assigned [11, 111]. Accordingly, all four 
CeO2 NMs are categorized as active, which confirms the 
in vitro assignment.
For an in-depth in vitro-in vivo comparison of the test 
results recorded for the four CeO2 NMs, the in  vitro 
data were further compared to specific BALF find-
ings that are directly related to AM-induced alterations 
of the in vivo rat lung, i.e. absolute values of total cells, 
AM, PMN as well as total protein concentration. By con-
trast to the above-mentioned particle surface area-based 
in vitro ranking, the following ranking of cytotoxicity is 
achieved when using the mass-based in  vitro data: Al-
doped CeO2  >  CeO2 NM-211  =  nano-CeO2  >  CeO2 
NM-212. As presented in further detail in the Addi-
tional file 1: Table S2, the BALF findings [11, 111] allow 
the following conclusions on in vivo AM-related pulmo-
nary alterations: Al-doped CeO2 and nano-CeO2 dose 
dependently decreased the number of AMs in the BALF 
and increased PMN counts and total protein concentra-
tion alike, whereas the corresponding effects elicited by 
CeO2 NM-211 and CeO2 NM-212 were approx. 60  % 
lower over the entire concentration range. Hence, even 
though the four different CeO2 NMs were assigned the 
same STIS NOAEC of <0.5  mg/m3, there were gradual 
differences in BALF parameters at nominally identical 
conditions of NM in the inspired air. Also the lung bur-
dens recorded for the four different CeO2 NMs upon 
5-day inhalation exposure differed [11, 111]. These differ-
ences are partly reflected by the in vitro tests in which Al-
doped CeO2 was clearly more bioactive than e.g., CeO2 
NM-212, at least in the low to middle dose range.
Amorphous SiO2 NMs
Colloidal SiO2.naked is assigned as in vitro active and its 
surface‑functionalized variants (SiO2.PEG, SiO2.amino, 
and  SiO2.phosphate) as  in  vitro passive For all four 
colloidal SiO2 NMs, significant in  vitro LOAECs were 
recorded for all four test parameters with the exception 
of GLU for SiO2.phosphate. However, as a rule, these sig-
nificant LOAECs by far exceeded the threshold value of 
6000  mm2/mL. Only for SiO2.naked, LDH and TNF-α 
attained 4500 mm2/mL, each, and for SiO2.amino, TNF-α 
attained this same value. Accordingly, only for the non-
surface functionalized SiO2.naked, two parameters with 
significant in vitro LOAECs below 6000 mm2/mL, i.e., the 
threshold for biologically relevant, particle-specific (i.e., 
non cellular overload-induced) effects, were recorded. 
In conclusion, SiO2.naked is assigned as in  vitro active, 
whereas its surface-functionalized variants SiO2.PEG, 
SiO2.amino, and SiO2.phosphate are assigned as passive.
In vivo categorizations confirm both  SiO2.naked activity 
and the passivity of the surface‑functionalized SiO2 At 10 
and 50 mg/m3, SiO2.naked evoked dose-dependent signs 
of inflammation in the rat STIS [11]. Three days after the 
final exposure, the most predominant significant effect in 
the BALF was an increased PMN count that was accom-
panied by slightly elevated BALF lymphocyte counts and 
moderately increased numbers of blood PMNs. In histo-
pathological evaluation, multifocal macrophage aggre-
gates were observed in the lung that exacerbated towards 
a slight multi-focal pulmonary inflammation by the end of 
the 3-week exposure free period. Accordingly, a NOAEC 
of 2.5  mg/m3 was assigned to SiO2.naked [11]. By con-
trast, no adverse effects were observed after inhalation 
exposure to up to 50  mg/m3 SiO2.PEG, SiO2.phosphate, 
or SiO2.amino, and the NOAEC for these materials was 
assessed as being ≥50 mg/m3 [11]. Based upon the in vivo 
STIS data, SiO2.naked is categorized as active NM and 
SiO2.PEG, SiO2.phosphate, and SiO2.amino as passive 
NMs, which confirms the in vitro assignment.
SiO2 NM‑200 and  NM‑203 are assigned as  in  vitro 
active Both precipitated SiO2 NM-200 and pyrogenic 
SiO2 NM-203 consistently elicited significant LDH, 
GLU and TNF-α release at 22.5  μg/mL, each. For all 
three parameters, this corresponds to significant in vitro 
LOAECs of 4253 and 4500  mm2/mL, for SiO2 NM-200 
and NM-203, respectively. Accordingly, for both dry-
powder amorphous SiO2 NMs, two parameters, each, 
ranged below the threshold value of 6000 mm2/mL, and 
both SiO2 NM-200 and NM-203 are assigned as active.
In vivo categorization confirms SiO2 NM‑200 and NM‑203 
activity For precipitated SiO2 NM-200 and pyrogenic 
SiO2 NM-203, STIS data were available for precipitated 
Zeosil® 45 and pyrogenic Cab-O-Sil® M5. The equiva-
lence of these materials to SiO2 NM-200 and NM-203, 
respectively, has been established based upon concord-
ance in production process and minimum degree of mate-
rial purity as well as comparability of specific surface area 
and agglomerate size [80, 112, 113]. In the rat STIS pub-
lished by Arts et al. [80], test material concentrations of 1, 
5, and 25 mg/m3 were applied, and 1 mg/m3 was recorded 
as NOAEC for both SiO2 NM-200 and NM-203, whereas 
5  mg/m3 was assessed as LOAEC. For SiO2 NM-200, 
increased weights of the lungs and lung-associated lymph 
nodes (LALNs) as well as an inflammatory response of 
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the lung tissue were recorded at 5 and 25  mg/m3 that 
were accompanied by dose-dependently increased PMN 
counts, enzyme activities, and protein levels in the BALF. 
For SiO2 NM-203, increased lung weights and hyper-
trophy of the bronchiolar epithelium were significant in 
the 5 and 25  mg/m3 test groups. The LALNs contained 
increased silica levels, and, again, dose-dependently 
increased PMN and macrophage counts in the BALF 
indicated inflammatory reactions. For both materials, all 
effects were fully reversible within 3 months post-expo-
sure [80]. Based upon the in vivo STIS data, SiO2 NM-200 
and NM-203 are categorized as active, which confirms the 
in vitro assignment.
Passive metal oxide and metal sulphate NMs (AlOOH, BaSO4, 
Fe2O3, ZrO2)
AlOOH is assigned as  in  vitro passive AlOOH (boe-
hmite) elicited dose-dependent and significant increases 
of LDH and TNF-α (significant in  vitro LOAECs: 9450 
and 18,900  mm2/mL, respectively). Hence, even though 
significant LOAECs were recorded for two param-
eters, both values ranged well above the threshold value 
of 6000  mm2/mL indicating that the observed effects 
were elicited under in vitro cellular overload conditions. 
Accordingly, these effects are assessed as not-particle spe-
cific, and AlOOH is assigned as passive.
In vivo categorization confirms AlOOH passivity The 
AlOOH NM included in the present study (PPS: 40 nm; 
BET surface area: 105 m2/g) and a smaller AlOOH variant 
(PPS: 10 nm; BET surface area: 182 m2/g) were submit-
ted to a 28-day rat sub-acute inhalation study followed by 
a 3-month post-exposure observation period [58]. In this 
study, no adverse effects were recorded at AlOOH aerosol 
concentrations of 0.4 or 3 mg/m3. Pulmonary inflamma-
tion (recorded by significantly altered BALF parameters, 
increased lung and LALN weights and histopathologi-
cal findings) was observed at 28  mg/m3 AlOOH. How-
ever, these effects were only elicited by cumulative doses 
exceeding approx. 1 mg AlOOH/g lung at the end of the 
28-day exposure period [58]. Since the concentration 
dependence and time-course changes of aluminum lung 
burden demonstrated a precipitous increase in elimina-
tion half-time at aerosol concentrations of 28  mg/m3, 
Pauluhn assessed these findings as being consistent with 
pulmonary overload [58]. An earlier intratracheal instil-
lation study confirmed these results indicating a NOAEC 
of 0.6 mg/rat lung, whereas reversible increases in BALF 
PMN and total protein levels were recorded at bolus 
doses of 1.2 mg/rat lung [84]. Since AlOOH was tested for 
28 days (i.e., four consecutive 5-day exposure periods), the 
NOAEC of 3 mg/m3 that Pauluhn [58] recorded for this 
material was converted to a 5-day NOAEC by multiplying 
it by a factor of four [94]. In accordance with this calcu-
lated 5-day NOAEC of 12 mg/m3, AlOOH is categorized 
as passive, which confirms the in vitro assignment.
BaSO4 NM‑220 is assigned as  in  vitro passive BaSO4 
NM-220 did not elicit any cellular effects that differed 
from the vehicle or corundum controls. Therefore, BaSO4 
NM-220 is assigned as passive.
In vivo categorization confirms BaSO4 NM‑220 passiv‑
ity No adverse effects were observed in a rat STIS after 
inhalation exposure to up to 50  mg/m3 BaSO4 NM-220 
[11]. Accordingly, BaSO4 NM-220 is categorized as pas-
sive, which confirms the in vitro assignment.
Fe2O3 is assigned as  in  vitro passive For Fe2O3 (hema-
tite), the only significant LOAEC was recorded for 
TNF-α (8266  mm2/mL). This one in  vitro LOAEC fur-
ther exceeded the threshold value of 6000  mm2/mL. Of 
note, the cytotoxic effects elicited by this nanosized Fe2O3 
were equal to or lower than those of its bulk counterpart, 
whereas the amount of sedimented test material appeared 
comparable (data not shown). Since only one parameter 
was affected, nanosized Fe2O3 is assigned as passive.
In vivo categorization confirms Fe2O3 passivity Inhala-
tion exposure to up to 30 mg/m3 Fe2O3 (or its non-nano-
sized counterpart; data not shown) in a STIS did not cause 
any adverse effects in the rat lung as was determined by 
BALF evaluation, hematology and histopathological eval-
uation [79]. Based upon this in vivo study, Fe2O3 (just as 
its non-nanosized counterpart) is categorized as passive, 
which confirms the in vitro assignment.
ZrO2.TODA and  ZrO2.acrylate are assigned as  in  vitro 
passive ZrO2.TODA and ZrO2.acrylate dose-depend-
ently and significantly increased LDH, TNF-α, and H2O2 
formation, and ZrO2.acrylate additionally GLU. However, 
apart from the LDH value recorded for ZrO2.TODA (in 
vitro LOAEC: 5265 mm2/mL), which laid just below the 
6000  mm2/mL threshold, all other significant in  vitro 
LOAECs recorded for either ZrO2.TODA or ZrO2.
acrylate exceeded the threshold value. Accordingly, both 
ZrO2.TODA and ZrO2.acrylate are assigned as passive.
In vivo categorization confirms ZrO2.TODA and  ZrO2.
acrylate passivity No adverse effects were observed in a 
rat STIS after inhalation exposure to up to 50 mg/m3 ZrO2.
acrylate or ZrO2.TODA [11]. In rat intratracheal instilla-
tion studies, bolus dose-NOAECs of 0.6 and 1.2  mg/rat 
lung were recorded for ZrO2.TODA and ZrO2.acrylate, 
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respectively [114]. Based upon these in vivo studies, both 
ZrO2.TODA and ZrO2.acrylate are categorized as passive, 
which confirms the in vitro assignment.
Nanosized organic pigments
DPP Orange N is assigned as in vitro passive DPP Orange 
N elicited a significant increase of TNF-α (in vitro LOAEC 
2880 mm2/mL) that ranged well below the threshold value 
of 6000 mm2/mL. However, since LDH, GLU, and H2O2 
formation were not significantly altered, the premise that 
at least two of the four parameters had to be altered to 
indicate NM activity was not met. Of note, also the bulk 
counterpart to DPP Orange N, DPP Orange B, did not 
elicit relevant cytotoxicity in the in  vitro NR8383 AM 
assay (data not shown). Accordingly, DPP Orange N (and 
DPP Orange B) are assigned as passive.
In vivo categorization confirms DPP Orange N passiv‑
ity Inhalation exposure to up to 30 mg/m3 DPP Orange 
N in a STIS did not cause any adverse effects in the rat 
lung as was determined by BALF evaluation, hematology 
and histopathological evaluation [79]. For the respective 
bulk material DPP Orange B, high aerosol concentrations 
of 30  mg/m3 slightly increased total cell count, PMN, 
MCP-1 and osteopontin in the BALF (data not shown). 
Based upon these in vivo studies, DPP Orange N (just as 
DPP Orange B) are categorized as passive, which confirms 
the in vitro assignment.
Pigment Blue 15:1 is assigned as in vitro active Pigment 
Blue 15:1 elicited dose-dependent increases of LDH and 
GLU with significant LOAECs of 4770  mm2/mL, each. 
(The slightly blue colouration of the supernatants could 
be corrected for via cell-free controls.) Accordingly, two 
parameters had significant LOAECs ranging below the 
threshold value of 6000  mm2/mL. Based upon these 
in vitro findings, Pigment Blue 15:1 is classified as active.
In vivo categorization indicates Pigment Blue 15:1 passiv‑
ity, thereby refuting the in vitro assignment as over‑predic‑
tive For Pigment Blue 15:1, a STIS NOAEC of 30 mg/
m3 was recorded [79]. At this aerosol concentration, blue 
pigment-laden AMs were observed in the lung paren-
chyma and LALNs. Further, slight epithelial hypertrophy 
or hyperplasia was noted in terminal bronchioles that 
however were assessed as rather reflecting the challenged 
biological clearance mechanism than adverse reactions. 
All findings were fully reversible within the 3-week post-
exposure period. Based upon this in vivo study, Pigment 
Blue 15:1 is categorized as passive. Accordingly, for this 
pigment, the in vitro NR8383 AM assay over-predicted its 
toxic potential in the rat STIS.
Graphite nanoplatelets
Graphite nanoplatelets are assigned as  in  vitro pas‑
sive Graphite nanoplatelets elicited significantly 
increased GLU and TNF-α levels (in vitro LOAECs, 3330 
and 6660  mm2/mL, respectively. Accordingly, only one 
parameter (GLU) ranged below the threshold value of 
6000 mm2/mL. Based upon these findings, graphite nano-
platelets are assigned as passive.
In vivo categorization confirms passivity of graphite nano‑
platelets Inhalation exposure to up to 50 mg/m3 graphite 
nanoplatelets in a STIS did not cause any adverse effects 
in the rat lung as was determined by BALF evaluation, 
hematology and histopathological evaluation [82]. Based 
upon this in vivo study, graphite nanoplatelets are catego-
rized as passive, which confirms the in vitro assignment.
Summary of in vitro–in vivo comparisons
In summary, for 19 of the 20 test materials, the in vitro 
NR838 AM assay addressing extracellular release of 
LDH, GLU, TNF-α and H2O2 correctly predicted in vivo 
activity or passivity in the rat STIS. Pigment Blue 15:1 
was the only material that tested false positive: Based 
upon the significant in vitro LOAECs that ranged below 
the threshold value of 6000 mm2/mL for LDH and GLU 
(each: 4770 mm2/mL), 2 of the 4 in vitro parameters were 
positive. This resulted in Pigment Blue 15:1 assignment 
as active, whereas it had been categorized as passive 
based upon the high STIS NOAEC of 30 mg/m3.
By contrast, for SiO2.amino, ZrO2.TODA, DPP Orange 
N, and graphite nanoplatelets, only one parameter each 
tested positive with significant in vitro LOAECs ranging 
below the threshold value of 6000 mm2/mL. ZrO2.TODA 
only triggered LDH, graphite nanoplatelets only triggered 
GLU, and SiO2.amino and DPP Orange N each only trig-
gered TNF-α release. By definition, this in vitro outcome 
resulted in their assignment as passive, and this result 
was confirmed by the in vivo data available for all four of 
these test materials.
Applying the Cooper statistics [93], the in vitro NR8383 
AM assay performed under the conditions of the present 
study had a specificity of 91 % and a sensitivity of 100 % 
with an overall accuracy of 95 %. The rates for negative 
and positive prediction were 90 and 100 % (Table 4).
Testing against a particulate benchmark material as 
a NC is mandatory in an empirical assay, since it pro-
vides information on the reliability and reproducibility 
of the behaviour of the cells under loading conditions. 
When evaluating all test results against the correspond-
ing values recorded for the negative (albeit micron-sized) 
benchmark material corundum (Additional file  1: Table 
S1), Pigment Blue 15:1 was again assessed false positive. 
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Since the test results obtained for corundum were slightly 
higher than those recorded for the particle-free vehicle 
control, the corundum-based evaluation resulted in some 
minor deviations from the vehicle control-based evalua-
tion. This, however, resulted in a number of statistically 
relevant differences. Using the corundum-based evalua-
tion, SiO2 NM-203 was assessed ‘false negative’ (only one 
significant LOAEC  <  6000  mm2/mL was recorded, i.e., 
for GLU). Furthermore, ZrO2.TODA and SiO2.phosphate 
exhibited one positive finding, each. A sharp demarca-
tion line between active and passive materials will be 
prone to erroneous decisions. Therefore, the premise had 
been set that at least two of the four parameters had to 
be altered to assign a material as active. Notwithstanding, 
false negative findings are detrimental for regulatory tox-
icity testing, and for this reason the statistical evaluation 
against untreated cells proved superior to the evalua-
tion against the negative benchmark material corundum. 
Accordingly, in the subsequent discussion, only the vehi-
cle-control-based evaluation is addressed.
Discussion
In the present study, the in vitro NR8383 AM assay eval-
uating extracellular release of LDH, GLU, TNF-α and 
H2O2 under standardized conditions using protein-free 
culture medium proved highly accurate in distinguishing 
active from passive inorganic NMs or nanosized organic 
pigments. All nine test materials that had been catego-
rized as active using the STIS NOAEC-based threshold 
value of <10  mg/m3 laid down by Arts et  al. [33] were 
correctly identified as active. Further, of the 11 test mate-
rials that had been categorized as passive (i.e., inert) by a 
STIS NOAEC of 10 mg/m3 or higher, only one test mate-
rial (Pigment Blue 15:1) was tested false positive in the 
in vitro NR8383 AM assay. For the other ten test materi-
als that had been categorized as passive using the STIS 
NOAEC, the in  vitro data correctly predicted in  vivo 
passivity.
Test protocol, prediction model, and threshold values
All 9 NMs that were assigned as active elicited elevated 
levels of extracellular LDH in the in vitro NR8383 AM 
assay. To increase the robustness of the assay and reduce 
the number of false positives, it had been defined that 
≥2 of the 4 in  vitro parameters had to be positive in 
order to assign a test material as active. For 3 of the 9 
active NMs, each, the increased LDH levels coincided 
with increased GLU levels (SiO2 NM-200 and NM-203 
and Pigment Blue 15:1), TNF-α levels (nano-CeO2 and 
CeO2 NM-211 and NM-212) or GLU plus TNF-α lev-
els (TiO2 NM-105, ZnO NM-111, Al-doped CeO2). Also 
for the non-nanosized PC quartz DQ12, significantly 
elevated LDH, GLU and TNF-α were recorded, and a 
significant LDH level as sole affected parameter (that 
hence did not result in NM assignment as active) was 
recorded for ZrO2.TODA.
By contrast, significant H2O2 formation below the 
in  vitro threshold value of 6000  mm2/mL was never 
recorded, neither as sole affected parameter, nor in 
combination with another affected parameter. Of note, 
however, a moderate to significant H2O2 formation 
was observed for the colloidal test materials (i.e., SiO2.
naked and its surface functionalized variants as well as 
the surface functionalized ZrO2 NMs). The mechanism 
by which, e.g., SiO2.phosphate induces H2O2 formation 
remains unknown, but it may be related to non-specific 
receptor activation. However, apparently, it does not 
depend on the presence of diffusible nanoparticles, since 
only three of the H2O2-inducing NMs (i.e., SiO2.naked, 
SiO2.amino, and SiO2.phosphate) remained dispersed in 
the nanosize under the testing conditions of the present 
study.
It might be questioned whether the determination 
of ROS formation is essential for the in  vitro NR8383 
AM assay, especially since the STIS protocol does not 
foresee a directly corresponding parameter. Neverthe-
less, the authors of the present study suggest maintain-
ing H2O2 formation as fourth parameter for the in vitro 
NR8383 AM assay. Different reaction patterns observed 
for different types of test materials may provide a first 
insight into their specific toxicological mechanisms 
which may further provide relevant information for the 
grouping of NMs [3, 33, 79] or the determination of 
adverse-outcome-pathways [115]. In this respect, also the 
Table 4 Determination of the accuracy, sensitivity and specificity of the in vitro NR8383 alveolar macrophage assay
Comparison of altogether 20 in vitro test results (cf. Table 3) to in vivo results from rat short-term inhalation studies applying the Cooper statistics [93]
Test material activity, STIS Test material passivity, STIS SUM
Test material activity, in vitro 9 1 10 90 % positive prediction
Test material passivity, in vitro 0 10 10 100 % negative prediction
SUM 9 11 20
100 % sensitivity 91 % specificity
Accuracy 95 %
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observation that only some NMs elicited significant H2O2 
formation requires further investigations.
AMs were selected as test system for the present study 
because the inflammatory effects that NMs may elicit in 
the rat lung upon short-term inhalation are considered to 
emanate at least in part from stimulated or compromised 
AMs. Accordingly, the mechanisms leading to pulmonary 
inflammation and which are reflected in the correspond-
ing NOAECs are based upon AM effects. Importantly, in 
developing the test protocol for the in vitro NR8383 AM 
assay, high accuracy of the in vitro assay was achieved by 
expressing data using surface area-based dose metrics 
(mm2/mL) and by combining the in vitro threshold value 
of <6000  mm2/mL with the ‘at least 2 out of 4′ predic-
tion model to assign a test material as active. The in vitro 
threshold value of 6000 mm2/mL has been set as a versa-
tile measure to reflect the highest in  vitro ‘non-overload’ 
dose under the conditions of the macrophage assay. Sur-
face area-based dose metrics are widely accepted for the 
in vitro assessment of NMs since their cellular effects are 
conveyed by their surface [95–99, 116–120]. By contrast, 
prior to the present study, application of a surface area-
based threshold value in an in  vitro AM assay to distin-
guish active from passive NMs had not yet been suggested.
As outlined in “Definition of in  vitro threshold value” 
section, the threshold of 6000  mm2/mL was derived 
from 4000  μm2/NR8383 cell. One must be aware that a 
sharply defined threshold value bears some uncertainty 
and should include some margin of safety. In this sense 
this threshold value has been derived from in vivo find-
ings: Since NR8383 cells widely resemble in vivo rat AMs 
both in terms of morphology and biological reactivity, 
4000 μm2/NR8383 cell may be multiplied with the total 
number of AMs per rat lung (i.e., 1–2 × 107 [54]), result-
ing in a calculated particle surface area-based threshold 
for the rat lung of 4–8  ×  1010  μm2 (corresponding to 
0.04–0.08 m2). Since a rat lung weighs approx. 1 g [121], 
the same value applies when expressing the particle 
surface area-based threshold per gram lung tissue (i.e., 
0.04–0.08 m2/g lung tissue). Interestingly, an earlier study 
addressing the sub-chronic pulmonary effects of inhaled 
TiO2 and BaSO4 NMs in rats suggested that the pulmo-
nary overload of these poorly soluble particles begins 
at 0.02–0.03  m2/g lung tissue [95]. Hence, the in  vitro 
threshold values applied in the present study is approx. 
twofold higher as it would be if the value from Tran et al. 
[95] was applied. This difference may be tolerable due 
to some uncertainties of the above-made calculations 
such as dynamically changing macrophage populations. 
Importantly, since materials that elicit adverse effects 
below the calculated threshold of 0.04–0.08  m2/g lung 
tissue are categorized as active in the present study, this 
higher threshold is conservative.
Taking into account the specific BET surface areas for 
different NMs, the calculated in vivo overload threshold 
of 0.04–0.08  m2/lung is equivalent to, e.g., 0.2–0.4  mg 
SiO2.naked (BET: 200  m2/g); 0.6–1.2  mg CeO2 NM-212 
(BET: 66  m2/g); or 0.85–1.7  mg TiO2 NM-105 (BET: 
47 m2/g). Accordingly, any in vivo adverse effect observed 
below these lung burdens should indicate test material-
specific activity in the non-overload range.
However, to convert the in vivo overload threshold of 
0.04–0.08 m2/lung to the mass-based aerosol concentra-
tion (i.e., mg/m3), NM lung deposition needs to be taken 
into account. Importantly, lung burden, as measured 
after 5-day exposure under STIS conditions, is not only 
concentration-dependent, but also material-depend-
ent [11]. Hence, also the in vivo overload threshold will 
be material-dependent. For instance, if a specific NM 
is highly soluble or has a low pulmonary deposition, its 
apparent lung burden may be low, and the maximum 
‘non-overload’ aerosol concentration may be higher than 
for an insoluble NM that further has a high pulmonary 
deposition. Moreover, material properties influencing 
lung clearance may play a role. For instance, exposure to 
0.5 mg/m3 CeO2 NM-212 in a rat STIS resulted in a lung 
burden of 0.011  mg/lung directly after 5  days of expo-
sure and decreased to 0.006  mg/lung by the end of the 
21-day post-exposure period. By contrast, exposure to 5 
and 25 mg/m3 of this same material yielded higher lung 
burdens with only little decrease during the post-expo-
sure observation period, indicating impaired clearance 
[111]. Also the lung burdens recorded for CeO2 NM-212 
were approx. twofold higher than the ones recorded for 
CeO2 NM-211 under identical conditions [111]. Accord-
ingly, precise comparisons of in  vitro and in  vivo data 
recorded for a given test material require consideration 
of the measured lung burden (or of a reliable calculation 
thereof ).
However, for practical reasons, i.e., for the prediction of 
NM activity or passivity under routine regulatory toxic-
ity testing conditions, it appears advantageous to use the 
fixed in  vitro threshold value of 6000  mm2/mL since it 
is easy to apply and further includes a margin of safety. 
Thereby, it is conservative: In the present study, it did not 
generate any false negative results. By contrast, for the 
time being, the occurrence of few false positive results 
(i.e., 1 out of 11 in the present study) cannot be avoided. 
Nevertheless, a low false positive rate does not prevent 
incorporation of the in  vitro NR8383 AM assay into a 
regulatory framework for the hazard assessment of NMs.
Finally, the in vitro threshold of 6000 mm2/mL is com-
pared to the threshold value of 10  μg/cm2 cell culture 
surface area that Kroll et al. [17] calculated as indicating 
in vitro cellular overload conditions. Of note, Kroll et al. 
related their threshold value to the entire rat lung surface 
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area, but not to the pool of AMs. As presented above, 
the particle surface area-based in vitro threshold value of 
6000 mm2/mL corresponds to 3600 mm2/cm2 cell culture 
surface area (for a cell culture volume of 200  μL). BET 
surface areas of the test materials applied in the present 
study ranged from 15  m2/g (i.e., 15  mm2/μg) for ZnO 
NM-111 to 200 m2/g (i.e., 200 mm2/μg) for the colloidal 
SiO2 NMs and pyrogenic SiO2 NM-203. Accordingly, for 
ZnO NM-111, the 6000 mm2/mL threshold value equals 
240  μg/cm2; for test materials with a BET surface area 
of approx. 60  m2/g (CeO2 NM-211 or DPP Orange N) 
it equals 60 µg/cm2, and for the mentioned SiO2 NMs it 
equals 18 μg/cm2. Therefore, the in vitro threshold set in 
the present study is higher than the in vitro threshold set 
by Kroll et al. [17]. However, this is not surprising since 
the threshold set in the present study considers the pool 
of AMs as a cell compartment that actively collects parti-
cles, both in vitro and in vivo.
Applicability domain of the in vitro NR8383 AM assay
All test materials that were identified as active in  vitro 
or in vivo elicited inflammatory effects in the rat lung. In 
the STIS, this was indicated by elevated PMN counts in 
the BALF that frequently coincided with increased total 
protein values and enzyme activities. These early pro-
inflammatory reactions became evident and were easily 
quantifiable by BALF analysis, whereas histopathological 
evaluation mostly revealed moderate alterations of the 
lung tissue that were possibly secondary to the inflam-
mation. Accordingly, the in vitro determination of a NM’s 
activity allows predicting its inflammatory potential in 
the rat lung. This may include cytotoxic or AM-activating 
effects upon inhalation and deposition in the rat lung, 
and/or the evolvement of inflammatory responses sec-
ondary to its AM-activating effects.
Although the response of a NR8383 cell to a NM may, 
to a certain degree, be taken as being representative 
for other cells as well [68, 69], AM-independent, direct 
effects of NMs on epithelial cells or other pulmonary 
cells, which may also contribute to the overall pulmonary 
response to NMs (e.g., the epithelial cytokine response) 
are not covered by the in vitro NR8383 AM assay. Other 
in vitro test systems than AMs may reflect epithelial dis-
orders evolving in the lung [122]. Nevertheless, also AMs 
may be suitable to assess such effects since they are either 
directly or indirectly involved in many pulmonary disor-
ders. For instance, an impaired lung clearance resulting 
from compromised AM activity may lead to progres-
sive pulmonary inflammation followed by e.g., fibrosis 
or neoplastic transformation. This is highlighted by the 
examples of quartz DQ12 or CeO2 NMs. These materials 
were assigned as active in the in vitro NR8383 AM assay. 
Upon chronic inhalation exposure, both materials may 
elicit fibrotic alterations of the lung. Of note, however, no 
neoplastic changes were reported upon treatment with 
CeO2 NMs [105, 109, 123].
As the spectrum of test materials selected for the pre-
sent study and further in-house experience reveal, the 
in  vitro NR8383 AM assay is applicable to poorly solu-
ble low-toxicity particles (PSLT [124]) that are also called 
respirable granular biodurable particles (GBP [32]). Simi-
larly, nuisance or inert dusts may be assessed, as long as 
they may be dispersed in the culture medium. Also par-
ticles retrieved from air filters, such as welding fumes or 
particles released from dental materials upon grinding, 
have been tested using the standard concentration range 
of 22.5–180  μg/mL. Particle agglomeration and gravita-
tional settling were found to enhance the delivery of the 
applied dose to the AMs at the bottom of the culture ves-
sels. In vitro particokinetics (i.e., particle size distribution 
and particle agglomeration) were controlled with phase 
contrast microscopy combined with tracking analysis of 
the supernatant. In fact, only 7 of the 20 test materials 
(SiO2.naked, SiO2.amino, SiO2.phosphate, SiO2 NM-203, 
Fe2O3, and the two organic pigments) remained at least 
partially dispersed in the culture media. As a result, the 
effective cellular dose of these materials cannot be deter-
mined with certainty using the simple microscopic char-
acterization methods applied in the present study.
Nevertheless, there are indeed NMs which cannot be 
successfully tested in the in vitro NR8383 AM assay for 
technical reasons. For instance, while MWCNT NM-401 
could be assessed (data not shown), other MWCNTs 
could not be dispersed sufficiently well to allow testing. 
Materials, which form agglomerates that float in suspen-
sion or which escape uptake by the AMs by adhering 
to the vessel walls or by gathering at the surface due to 
low buoyant density, can also not be assessed. Further-
more, materials which strongly interfere with the opti-
cal read out may cause problems, since the transmitted 
light levels may by too low to be corrected by the cell-free 
controls. Of note, however, the orange, red, and blue pig-
ments could be evaluated since the AMs took them up 
and completely cleared the cell culture bottom from col-
oured agglomerates.
Test material effects
In the following, the specific in  vitro effects of the test 
materials observed in the in vitro NR8383 AM assay are 
compared to the findings reported for identical or com-
parable test materials available in the published literature.
Active metal oxide NMs (TiO2, ZnO, CeO2)
Generally, the in vitro findings recorded for the six metal 
oxide NMs that were identified as active (TiO2 NM-105, 
ZnO NM-111, and all four tested CeO2 NMs) stand in 
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line with results from other in  vitro or in  vivo studies. 
Recently, anatase TiO2 NM-101 has been found to elicit 
weak activating effects on HL-60 cells which may repre-
sent human neutrophil-like cells [125]. In the same study, 
the ion-shedding ZnO NM-110 and Ag NM-300 elicited 
much more pronounced cytotoxicity. Consistent with 
these findings, also uncoated and coated ZnO NMs (cf. 
“Active metal oxide NMs (TiO2, ZnO, CeO2)” section) as 
well as Ag NM-300K (data not shown) were recorded as 
active in the in vitro NR8383 AM assay. Even though rat 
STIS data are unavailable for Ag NM-300K, these find-
ings appear biologically relevant.
CeO2 NMs have a highly reactive surface which, apart 
from Ce4+ and Ce3+, is chiefly composed of oxygen and 
O2−. The change of oxidation state from 3+ to 4+ appears 
to determine the biological activity of CeO2 NMs. This 
may either result in ROS generating or ROS scavenging 
properties [21, 88]. Accordingly, different types of CeO2 
NMs may be expected to elicit contradictory reactions, 
and different CeO2 NMs have indeed been observed to 
be either ROS/H2O2 protective [126, 127] or toxic in rats 
[123] or in different types of cultured cells [68].
However, the four different CeO2 NMs were consist-
ently assigned as active both in vitro and in vivo. Never-
theless, based upon an in-depth evaluation of the data (cf. 
Additional file 1: Table S2), Al-doped CeO2 NMs elicited 
the most pronounced inflammatory reactions observed 
for CeO2 NMs in the present in vitro study (or in the pub-
lished in vivo STIS data reflecting AM-based reactions in 
the rat lung). Especially Al-doping of CeO2 NMs has been 
recognized to strongly increase the O2-binding capacity 
of this material [128]. It may be assumed that O2-surface 
binding may be involved in its in vitro or in vivo toxicity. 
Further in  vitro investigations should aim at addressing 
the specific mechanisms of toxicity or protective cellular 
effects that different types of CeO2 may elicit.
Amorphous SiO2 NMs
Of the four different colloidal SiO2 NMs submitted to the 
present study, only the unmodified SiO2.naked was tested 
positive in the rat STIS [11]. An instillation study with 
mice provided the same outcome for these same materi-
als [129]. Furthermore, it revealed a weak effect on PMN 
recruitment into the lungs for SiO2.amino and SiO2.
phosphate. In the present study, SiO2.amino elicited sig-
nificant TNF-α release (only this one parameter affected), 
whereas for SiO2.phosphate none of the four param-
eters were affected. The effects of SiO2.naked recorded 
in the present study occurred in the absence of protein, 
since protein coating with fetal calf serum mitigates the 
toxicity of SiO2 NMs [21, 130]. It may be assumed that 
the protein-binding capacity of amorphous SiO2 may 
affect specific inflammatory or toxic responses in  vivo. 
Concordantly, surface functionalization with PEG, amino 
or phosphate residue may reduce or affect protein bind-
ing, both in vitro and in vivo.
Passive metal oxide and metal sulphate NMs (AlOOH, BaSO4, 
Fe2O3, ZrO2)
Based upon the in  vitro NR8383 AM data, AlOOH 
and BaSO4 NM-220 were assigned as passive. This 
result stands in full concordance with previous studies 
using a broad spectrum of different cell lines, includ-
ing RAW264.7 macrophages, even though these stud-
ies were conducted in the presence of serum [17]. Also 
nanosized Fe2O3 (hematite) was assigned as passive. Its 
effects on LDH or GLU release were in the same range as 
its non-nanosized counterpart (data not shown). Hence, 
‘nanosize’ of this inorganic pigment does not appear to 
augment its hazard potential.
In the present study, ZrO2.TODA, but not ZrO2.
acrylate, elicited an increased LDH level (and a sig-
nificant in  vitro LOAEC was recorded for only this one 
parameter). ZrO2.TODA and ZrO2.acrylate also gradu-
ally differed with respect to the induced (albeit not sig-
nificant) release of GLU and H2O2. This may point to 
differences caused by the different surface functionali-
zations. These minor findings do not correspond to the 
outcomes of the available STISs where neither material 
caused any effects up to 50 mg/m3 [11]. Nevertheless, dif-
ferent STIS lung burdens were measured for ZrO2.TODA 
(693 μg) and ZrO2.acrylate (169 μg) after 5-day inhalation 
exposure to identical aerosol concentrations of 50 mg/m3 
[11], such that a final comparison cannot be made.
Nanosized organic pigments and graphite nanoplatelets
Coloured and dense materials are potentially difficult to 
evaluate in in vitro assays using colorimetric assays. Nev-
ertheless, in the present study the two nanosized organic 
pigments (just as the inorganic red pigment Fe2O3) had 
mostly settled by the end of the incubation period, and 
further particles could be removed from the superna-
tant by centrifugation before the optical measurements. 
Thereby, an acceptable degree of variation was ensured. 
Also the influence of the few remaining particles could 
be circumvented by subtracting the values obtained for 
the cell-fee controls. Whereas the particles that remained 
in suspension (and hence did not sediment towards the 
cells) are not expected to affect the effective dose reach-
ing the cells within the incubation period to a consider-
able extent, the precise effective cellular dose of these 
materials cannot be estimated.
For DPP Orange N only a dose-dependent formation 
of TNF-α was recorded, and just as its non-nanosized 
counterpart DPP Orange B, it was assigned as in  vitro 
passive. Hence, also for this organic pigment there is 
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no indication that the ‘nanosize’ increases its hazard 
potential.
Pigment Blue 15:1 significantly increased both LDH 
and GLU and the calculated values were below the 
threshold of 6000  mm2/mL. Thereby, this organic pig-
ment delivered the only false positive result since it did 
not elicit adverse effects in vivo in the rat STIS up to aer-
osol concentrations of 30 mg/m3 [79]. Even though Pig-
ment Blue 15:1 contains copper, this compound is tightly 
bound to the molecule, and ions are neither released in 
water, nor in biological media [79]. It must be underlined 
that the effects that Pigment Blue 15:1 elicited in  vitro 
were not severe: Even a mean cellular load of 30 pg/AM 
(equivalent to 45 μg/mL) did not lead to cell membrane 
damage (cf. Table 2). However, at this concentration, the 
GLU release from the intact cells was already increased, 
and both parameters were significantly affected at 90 
and 180  μg/mL. Even though no release of copper was 
measured, it is known that copper ions may affect GLU 
expression in cells [131–133]. Obviously, the dispar-
ity between the in vitro and STIS findings recorded for 
Pigment Blue 15:1 remains to be investigated in further 
detail.
Conclusion
Investigating a broad spectrum of 18 inorganic NMs and 
2 nanosized organic pigments, the in vitro NR8383 AM 
assay allowed distinguishing active from passive nanoma-
terials. AMs were selected as test system due to the pre-
dominant role these cells play in clearing the lung from 
inhaled particles. Further, many secondary pulmonary 
effects are also initiated or accompanied by AMs. The 
selected parameters, LDH, GLU, TNF-α and H2O2 for-
mation and release, in combination with the ‘at least 2 
out of 4’ prediction model proved easy to use and suitable 
for routine testing. Importantly, the model was highly 
efficient in predicting in  vivo STIS hazard potential. 
Recently, application of the in  vitro NR8383 AM assay 
within the DF4nanoGrouping Decision-making frame-
work for the grouping and testing of NMs has shown that 
this assay also allows grouping NMs by biological activity 
[33, 79]. When integrated into a tiered testing approach, 
such as the DF4nanoGrouping, the in vitro NR8383 AM 
assay may substantially reduce the need for animal test-
ing addressing the inhalation route of exposure. Further 
work should aim at validating this assay.
Additional file
Additional file 1: Table S1. Comparison of significant in vitro LOAECs 
(significant as compared to the negative benchmark material corundum) 
to NOAECs and LOAECs recorded in rat STISs. Table S2. Bioactivity of four 
types of CeO2 NMs in rat STISs as compared to cellular effects recorded in 
the in vitro NR8383 AM assay.
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